

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/01, 15/09, C12P 21/00	A1	(11) International Publication Number: WO 99/58661 (43) International Publication Date: 18 November 1999 (18.11.99)
<p>(21) International Application Number: PCT/AU99/00341</p> <p>(22) International Filing Date: 7 May 1999 (07.05.99)</p> <p>(30) Priority Data: PP 3445 8 May 1998 (08.05.98) AU</p> <p>(71) Applicant (for all designated States except US): DIATECH PTY. LTD. [AU/AU]; GPO Box 2434, Brisbane, QLD 4001 (AU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COIA, Gregory [AU/AU]; 73 Union Street, Brunswick, VIC 3056 (AU). HUDSON, Peter, John [AU/AU]; 36 Fuschia Street, Blackburn, VIC 3130 (AU). ILIADES, Peter [AU/AU]; 14 Robert Street, North Balwyn, VIC 3104 (AU). IRVING, Robert, Alexander [AU/AU]; 11 Honeysuckle Avenue, Mulgrave, VIC 3170 (AU).</p> <p>(74) Agent: F.B. RICE & CO.; 605 Darling Street, Balmain, NSW 2041 (AU).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
(54) Title: CONTINUOUS <i>IN VITRO</i> EVOLUTION		
(57) Abstract		

The present invention provides a method for the mutation, synthesis and selection of a protein which binds to a target molecule, the method comprising: (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, wherein the RNA-directed RNA polymerase replicates the mRNA molecule but introduces mutations thereby generating a population of mutant mRNA molecules; (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which result in the synthesis of a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant protein/mRNA complexes; (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule and recovering the mutant protein/mRNA complex(es) bound thereto.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONTINUOUS IN-VITRO EVOLUTION

FIELD OF THE INVENTION

5 The present invention relates to a method for mutating and selecting target binding proteins in a translation system; and to a polynucleotide construct for use in this method. The method of the present invention may be applied to the generation of molecules of diagnostic and therapeutic utility.

10 BACKGROUND OF THE INVENTION

In vitro evolution of proteins involves introducing mutations into known gene sequences to produce a library of mutant sequences, translating the sequences to produce mutant proteins and then selecting mutant proteins with the desired properties. This process has the potential for generating proteins with improved
15 diagnostic and therapeutic utilities. Unfortunately, however, the potential of this process has been limited by deficiencies in methods currently available for mutation and library generation.

For example, the generation of large libraries (eg beyond a library size of 10^{10}) of unique individual genes and their encoded proteins has proven difficult
20 with phage display systems due to limitations in transformation efficiency. A further disadvantage is that methods which utilise phage-display systems (Figure 1) require several sequential steps of mutation, amplification, selection and further mutation (Irving et al., 1996; Krebber et al., 1995; Stemmer, 1994; Winter et al., 1994).

25 Examples of procedures which have been used to date for affinity maturation of selected proteins, and particularly for the affinity maturation of antibodies, are set out in Table 1. All these methods rely on mutation of genes followed by display and selection of encoded proteins. The particular mutation that is chosen determines the diversity in the resulting gene library. *In vitro* strategies (Table 1)
30 are severely limited by the efficiency in transformation of mutated genes in forming a phage display library. In one *in vivo* cyclical procedure (Table 1 No.1), *E.coli* mutator cells were the vehicle for mutation of recombinant antibody genes. The *E.coli* mutator cells MUTD5-FIT (Irving et al., 1996) which bear a mutated DNAQ gene could be used as the source of the S-30 extracts and therefore allow
35 mutations introduced into DNA during replication as a result of proofreading errors. However, mutation rates are low compared to the required rate. For example, to

mutate 20 residues with the complete permutation of 20 amino acid requires a library size of 1×10^{26} , an extremely difficult task with currently available phage display methodology.

5

Table 1: Affinity maturation strategies

<i>In vivo</i>		Mechanism
1	Mutator cells	Random point mutations
2	SIP-SAP	Co-selection and infection with antibody-antigen pairs
<i>In vitro</i>		
3	DNA shuffling-sexual PCR	Recursive sequence recombination by DNA homology
4	Site directed mutagenesis over selected regions (CDRs)	Oligonucleotide-coded mutations
5	Chain shuffling	Sequential replacement of heavy or light chain domains using phage libraries
6	Error-prone PCR	Polymerase replication errors

1) Irving *et al.* (1996); 2a) Krebber *et al.* (1995); 2b) Duenas and Borrebaeck (1994); 3) Stemmer (1994), Stemmer *et al.* (1995); 4) Yang *et al.* (1995); 5a) Barbas *et al.* (1994); 5b) Winter *et al.* (1994); 6) Gram *et al.* (1992).

10

A selection method which enables the *in vitro* production of complex libraries of mutants which are continuously evolving (mutating) and from which a
15 desired gene may be selected would therefore provide an improved means of affinity maturation (enhancement) of proteins.

In vitro coupled transcription and translation systems

It is well known that a DNA plasmid containing a gene of interest can act as template for transcription when controlled by a control element such as the T7
20 promoter. It is also known that coupled cell -free systems may be used to simultaneously transcribe mRNA and translate the mRNA into peptides (Baranov *et al.* 1993; Kudilicki *et al.* 1992; Kolosov *et al.* 1992; Morozov *et al.* 1993; Ryabova *et al.* 1989, 1994; Spirin 1990; US 5556769; US5643768; He and Taussig 1997). The

source of cell free systems have generally been *E.coli* S-30 extracts (Mattheakis 1994; Zubay 1973) for prokaryotes and rabbit reticulocyte lysates for eukaryotes. Transcription/translation coupled systems have also been reported (US 5492817; US 5665563; US 5324637) involving prokaryotic cell free extracts (Mattheakis et al 5 1994) and eukaryotic cell free extracts (US 5492817; US 5665563) which have different requirements for effective transcription and translation. In addition, there are requirements for the correct folding of the translated proteins in the prokaryotic and eukaryotic systems. For prokaryotes, protein disulphide isomerase (PDI) and chaperones may be required. Generally in prokaryotes translated proteins are 10 folded after release from the ribosome; however, for correct folding of the newly translated protein attached (tethered) to the ribosome a C terminal anchor may also be necessary. An anchor is a polypeptide spacer that links the newly translated protein domain (s) to the ribosome. The anchor may be a complete protein domain such as an immunoglobulin constant region. In complete contrast to this, in 15 eukaryotic systems the protein is folded as it is synthesised and has no requirement for the addition of prokaryote PDI and chaperones. An anchor may however be beneficial in eukaryotic systems for spacing from, and correct folding of, the newly translated protein attached (tethered) to the ribosome.

Polypeptides synthesised *de novo* in cell-free coupled systems have been 20 displayed on the surface of ribosomes, since for example in the absence of a stop codon the polypeptide is not released from the ribosome. The mRNA ribosome protein complex can be used for selection purposes. This system mimics the process of phage display and selection and is shown in Figure 1. Features required for optimal display on ribosomes have been described by Hanes and Pluckthun 25 (1997). These features include removal of stop codons. However, removal of stop codons results in the addition of protease sensitive sites to the C terminus of the newly translated protein encoded by a *ssrA* tRNA-like structure. This can be prevented by the inclusion of antisense *ssrA* oligonucleotides (Keiler et al 1996).

RNA-directed RNA polymerases

30 Q β bacteriophage is an RNA phage with an efficient replicase (RNA-dependent RNA polymerases are termed replicases or synthetases) for replicating the single-strand genome of coliphage Q β . Q β replicase is error-prone and introduces mutations into the RNA calculated *in vivo* at 10^3 - 10^4 bases. The fidelity of Q β replicase is low and strongly biased to replicating its template (Rohde et al 35 1995). These teachings indicate that replication over a prolonged period leads to accumulation of mutated strands not suitable for synthesis of a desired protein.

Both + and - strands serve as templates for replicase; however, for the viral genome the + strand is bound by Q β replicase and used as the template for the complementary strand (-). In order for RNA replication to occur the replicase requires specific RNA sequence/structural elements which have been well defined
5 (Brown and Gold 1995; Brown and Gold 1996). A reaction containing 0.14 femtograms of recombinant RNA produces 129 nanograms in 30 mins (Lizardi et al 1988).

RNA-directed RNA polymerases are known to replicate RNA exponentially on compatible templates. Compatible templates are RNA molecules with secondary
10 structure such as that seen in MDV-1 RNA (Nishihara, T., et al 1983). In this regard, a vector has been described for constructing amplifiable mRNAs as it possesses the sequences and secondary structure (MDV-1 RNA) required for replication and is replicated *in vitro* in the same manner as Q β genomic RNA. The MDV-1RNA sequence (a naturally occurring template for Q β replicase) is one of a number of
15 natural templates compatible with amplification of RNA by Q β replicase (US-4786600); it possesses tRNA-like structures at its terminus which are similar to structures that occur at the ends of most phage RNAs which increase the stability of embedded mRNA sequences. Linearisation of the plasmid allows it to act as a template for the synthesis of further recombinant MDV-1 RNA. (Lizardi et al 1988).
20 Teachings in the art show that prolonged replication by Q β replicase of a foreign gene require that it be embedded as RNA within one of the naturally occurring templates such as MDV-1RNA.

SUMMARY OF THE INVENTION

25 The present inventors have now found that RNA directed RNA polymerases introduce mutations into synthesised mRNA molecules during replication in such a manner as to create a library of evolving (mutated) mRNA molecules. These mutated mRNA molecules vary in size due to insertions and deletions as well as point mutations and may be translated *in vitro* such that the corresponding proteins
30 are displayed, for example, on a ternary complex comprising ribosome, mRNA, and mRNA encoded *de novo* synthesised protein. The present inventors have also identified conditions in which a large proportion of proteins generated by the ribosome display process are in a correctly folded, functional form. Furthermore, the present inventors have identified conditions in which phage Q β replicase can
35 function in eukaryotic coupled transcription/translation systems to amplify RNA templates, incorporating mutations into mRNA.

The mRNA molecules in the preferred transcription/translation system of the present invention are in a continuous cyclic process of replication/mutation/translation leading to a continuous *in vitro* evolution (CIVE) process.

This CIVE process provides a novel method for *in vitro* evolution of proteins which avoids the limitation of numbers, library size and the time consuming steps inherent in previous affinity maturation processes.

Accordingly, in a first aspect the present invention provides a method for the mutation, synthesis and selection of a protein which binds to a target molecule, the method comprising:

- 10 (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, wherein the RNA-directed RNA polymerase replicates the mRNA molecule but introduces mutations thereby generating a population of mutant mRNA molecules;
- 15 (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which result in the synthesis of a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant protein/mRNA complexes;
- 20 (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule and recovering the mutant protein/mRNA complex(es) bound thereto; and
- (d) optionally releasing the mRNA molecules from the complex(es).

In a second aspect the present invention provides a method for the mutation, synthesis and selection of a protein which binds to a target molecule which includes:

- 25 (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which result in the synthesis of a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant protein/mRNA complexes;
- 30 (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule;

(d) repeating steps (a) to (c) one or more times, wherein the replicable mRNA molecule used in step (a) is the mRNA obtained from complex(es) selected in step (c);

(e) recovering mutant protein complexes bound to the target molecule(s);

5 and

(f) optionally releasing or recovering the mRNA molecules from the complex(es).

The mRNA from step (d) may be recycled through steps (a) to (c) without purification or isolation from the translation system.

10 In one embodiment, the mRNA from step (d) is recycled via step (a) while the mRNA is attached to the complex(es) obtained in step (c). In another embodiment, the mRNA is released from the complex(es) obtained in step (c) prior to recycling. The mRNA may be released from the complexes by any suitable mechanism. The mechanism may include raising the temperature of the incubation, or changing the
15 concentration of the compounds used to maintain the complexes intact.

In the context of the present invention, the mRNA may be recycled through steps (a) to (c) by sequential, manual steps. In a preferred embodiment, however, steps (a), (b), (c) and (d) are carried out simultaneously in a single or multiple chambered reaction vessel and the recycling occurs automatically within the vessel.

20 In the context of the present invention, the mRNA may be recycled through steps (a) to (c) by sequential, manual steps. In a preferred embodiment, however, steps (a), (b), (c) and (d) are carried out simultaneously in a single reaction vessel and the recycling occurs automatically within the vessel.

In another embodiment of the second aspect, the mRNA from step (d) is
25 isolated. The isolated mRNA may be transcribed into cDNA. The resulting cDNA may be cloned into a vector suitable for expression of the encoded protein.

It will be appreciated by those skilled in the art that any suitable complex may be used to link the translated proteins to their encoding mRNAs. For example, the complex may be a mitochondria or other cell organelle suitable for protein
30 display. In a preferred embodiment, the complex is an intact ternary ribosome complex. The ribosome complex preferably comprises at least one ribosome, at least one mRNA molecule and at least one translated polypeptide. This complex allows "ribosome display" of the translated protein. Conditions which are suitable for maintaining ternary ribosome complexes intact following translation are known.
35 For example, deletion or omission of the translation stop codon from the 3' end of the coding sequence results in the maintenance of an intact ternary ribosome

complex. Sparsomycin or similar compounds may be added to prevent dissociation of the ribosome complex. Maintaining specific concentrations of magnesium salts and lowering GTP levels may also contribute to maintenance of the intact ribosome complex.

5 It will be appreciated by those skilled in the art that preferred embodiments of the present invention involve coupled replication-translation-selection in a recycling batch process, and preferably, in a continuous-flow process (see, for example, Figure 4). Continuous-flow equipment and procedures for translation or
10 transcription-translation are known in the art and can be adapted to the methods of this invention by changing the composition of materials or conditions such as temperature in the reactor. Several systems and their methods of operation are reviewed in Spirin, A.S. (1991), which is incorporated by reference herein. Additional pertinent publications include Spirin et al. (1988); Rattat et al. (1990); Baranov et al. (1989); Ryabova et al. (1989); and Kigawa et al. (1991), all of which
15 are incorporated by reference herein.

By "translation system" we mean a mixture comprising ribosomes, soluble enzymes, transfer RNAs, and an energy regenerating system capable of synthesizing proteins encoded by exogenous mRNA molecules.

In a preferred embodiment, the translation system is a cell-free translation
20 system. Translation according to this embodiment is not limited to any particular cell-free translation system. The system may be derived from a eukaryote, prokaryote or a combination thereof. A crude extract, a partially purified extract or a highly purified extract may be used. Synthetic components may be substituted for natural components. Numerous alternatives are available and are described in
25 the literature. See, for example, Spirin (1990b), which is incorporated by reference herein. Cell free translation systems are also available commercially. In one embodiment of the present invention the cell-free translation system utilises an S-30 extract from *Escherichia coli*. In another embodiment, the cell-free translation system utilises a reticulocyte lysate, preferably a rabbit reticulocyte lysate.

30 The translation system may also comprise compounds which enhance protein folding. To this end, the present inventors have identified conditions in which an increased proportion of proteins produced by the ribosome display process are generated in a folded, functional form. These conditions include the addition of reduced and/or oxidised glutathione to the translation system at a
35 concentration of between 0.1mM and 10mM. Preferably, the translation system comprises oxidised glutathione at a concentration of between 2mM to 5mM.

Preferably, the translation system comprises oxidised glutathione at a concentration of about 2mM and reduced glutathione at a concentration of between 0.5 mM and 5mM.

5 In another embodiment of the present invention the translation system consists of or comprises a cell or compartment within a cell. The cell may be derived from a eukaryote or prokaryote.

A number of RNA-directed RNA polymerases (otherwise known as replicases or RNA synthetases) known in the art have been isolated and are suitable for use in the method of the present invention. Examples of these include bacteriophage RNA
10 polymerases, plant virus RNA polymerases and animal virus RNA polymerases. In a preferred embodiment of the present invention, the RNA-directed RNA polymerase introduces mutations into the replicated RNA molecule at a relatively high frequency, preferably at a frequency of at least one mutation in 10^4 bases, more preferably one mutation in 10^3 bases. In a more preferred embodiment the RNA-
15 directed RNA polymerase is selected from the group consisting of Q β replicase, Hepatitis C RdRp, Vesicular Stomatitis Virus RdRp, Turnip yellow mosaic virus replicase (Deiman et al (1997) and RNA bacteriophage phi 6 RNA-dependent RNA (Ojala and Bamford (1995). Most preferably, the RNA-directed RNA polymerase is Q β replicase.

20 The RNA-directed RNA polymerase may be included in the transcription/translation system as a purified protein. Alternatively, the RNA-directed RNA polymerase may be included in the form of a gene template which is expressed simultaneously with step (a), or simultaneously with steps (a), (b) and (c) of the methods of the first or second aspects of the present invention.

25 In a further preferred embodiment, the RNA-directed RNA polymerase may be fused with or associated with the target molecule. Without wishing to be bound by theory, it is envisaged that in some cases, the binding affinity of the translated protein may be greater than the affinity of the replicase for the mRNA molecule. The binding of the mutant protein/mRNA complex to a target molecule/ RNA-
30 directed RNA polymerase fusion construct would bring the mRNA into the proximity of the RNA-directed RNA polymerase. This may result in preferential further replication and mutation of mRNA molecules of interest.

RNA templates that are replicated by various RNA-dependent RNA polymerases are known in the art and may serve as vectors for producing replicable
35 mRNAs suitable for use in the present invention. Known templates for Q β replicase include RQ135 RNA, MDV-1 RNA, microvariant RNA, nanovariant RNAs, CT-RNA

and RQ120 RNA. Q β RNA, which is also replicated by Q β replicase, is not preferred, because it has cistrons, and further because the products of those cistrons regulate protein synthesis. Preferred vectors include MDV-1 RNA and RQ135 RNA. The sequences of both are published. See Kramer et al. (1978) (MDV-1 RNA) and
5 Munishkin et al. (1991) J (RQ135), both of which are incorporated by reference herein. They may be made in DNA form by well-known DNA synthesis techniques.

In a preferred embodiment of the first aspect of the present invention, the method further includes the step of transcribing a DNA construct to produce replicable mRNA. DNA encoding the recombinant mRNA can be, but need not be,
10 in the form of a plasmid. It is preferable to use a plasmid and an endonuclease that cleaves the plasmid at or near the end of the sequence that encodes the replicable RNA in which the gene sequence is embedded. Linearization can be performed separately or can be coupled with transcription-replication-translation. Preferably, however, linear DNA is generated by any one of the many available DNA
15 replication reactions and most preferably by the technique of Polymerase Chain Reaction (PCR). For some systems non-linearized plasmids without endonuclease may be preferred. Suitable plasmids may be prepared, for example, by following the teachings of Melton et al (1984a,b) regarding processes for generating RNA by transcription *in vitro* of recombinant plasmids by bacteriophage RNA polymerases,
20 such as T7 RNA polymerase or SP6 RNA polymerase. See, for example, Melton et al. (1984a) and Melton (1984b), which are incorporated by reference herein. It is preferred that transcription begin with the first nucleotide of the sequence encoding the replicable RNA.

In a further preferred embodiment the transcription is carried out
25 simultaneously in a single or multiple chambered reaction vessel, or reactor, with steps (a), (b), (c) of the method according to the first or second aspects of the present invention.

The target molecule may be any compound of interest (or a portion thereof) such as a DNA molecule, a protein, a receptor, a cell surface molecule, a metabolite,
30 an antibody, a hormone a bacterium or a virus.

In a preferred embodiment, the target molecule is bound to a matrix and added to the reaction mixture comprising the complex (displaying translated proteins). The target molecule may be coated, for example, on a matrix such as magnetic beads. The magnetic beads may be Dynabeads. It will be appreciated that
35 the translated proteins will competitively bind to the target molecule. Proteins with higher affinity will preferably displace lower affinity molecules. Thus, the method

of the present invention allows selection of mutant proteins which exhibit improved binding affinities for a target molecule of interest.

The present inventors have also made the surprising findings that minimal sequences derived from naturally occurring replicase templates, such as the MDV-1
5 template, are sufficient for the binding of Q β replicase. On the basis of this finding a novel construct suitable for transcription of replicable mRNA has been developed.

Accordingly, in a preferred embodiment of the first or second aspects of the present invention, the method further includes transcribing a DNA construct to produce a replicable mRNA molecule, wherein the DNA construct comprises:

10 (i) an untranslated region comprising a control element which promotes transcription of the DNA into mRNA and a ribosome binding site;

(ii) an open reading frame encoding the protein which binds to the target molecule; and

(iii) a stem-loop structure situated upstream of the open reading frame.

15 In a third aspect the present invention provides a DNA construct comprising:

(i) an untranslated region comprising a control element which promotes transcription of the DNA into mRNA and a ribosome binding site;

(ii) a cloning site located downstream of the untranslated region; and

(iii) a replicase binding sequence located upstream of the cloning site.

20 When used herein the phrase "replicase binding sequence" refers to a polynucleotide sequence which as a "loop-like" secondary structure which is recognised by a replicase (in particular, a replicase holoenzyme). Preferably, the replicase binding sequence does not include a full length RNA template for a replicase molecule. For example, preferably the phrase "replicase binding
25 sequence" does not include full length MDV-1 RNA or RQ135 RNA templates.

In a preferred embodiment, the replicase binding sequence is between 15 to 50 nucleotides in length, more preferably between 20 and 40 nucleotides in length. Preferably, the replicase binding sequence is recognised by Q β replicase.

In a further preferred embodiment, the sequence of the replicase binding
30 sequence comprises or consists of the sequence:

GGGACACGAAAGCCCCAGGAACCUUUCG.

In a further preferred embodiment, a second replicase binding sequence is included downstream of the cloning site.

Any suitable ribosome binding site may be used in the construct of the
35 present invention. Prokaryotic and eukaryotic ribosome binding sequences may be

incorporated depending on whether prokaryotic or eukaryotic systems are being used. A preferred prokaryotic ribosome binding site is that of the MS2 virus.

In a further preferred embodiment, the DNA construct includes a translation initiation sequence. Preferably, the translation initiation sequence is ATG.

5 It will be apparent to those skilled in the art that any gene of interest may be inserted into the cloning site in the DNA construct. In a preferred embodiment the gene(s) of interest is a nucleotide sequence coding for (i) a library of target binding proteins or (ii) a single target binding protein, where the target could include any of protein, DNA, cell surface molecules, receptors, antibodies, hormones, viruses or
10 other molecules or complexes or derivatives thereof.

A nucleotide sequence coding for an anchor domain may be fused 3' in frame with the gene of interest. The anchor domain may be any polypeptide sequence which is long enough to space the protein translated from the gene of interest a sufficient distance from the ribosome to allow correct folding of the molecule and
15 accessibility to its cognate binding partner. Preferably, the polypeptide has a corresponding RNA secondary structure which mimics that of a replicase template. In a preferred embodiment, the polypeptide is an immunoglobulin constant domain. Preferably, the polypeptide is a constant light domain. The constant light domain may be the first constant light region of the mouse antibody 1C3.
20 Preferably, the constant domain is encoded by the sequence shown in Figure 5a. Alternatively, the polypeptide may be the human IgM constant domain. In another embodiment the anchor may be selected from the group consisting of: the octapeptide "FLAG" epitope, DYKDDDDK or a polyhistidine₆ tag followed optionally by a translation termination (stop) nucleotide sequence. The translation
25 termination (stop) nucleotide sequence may be TAA or TAG. In some constructs of the present invention, no stop codons are present so as to prevent recognition by release factors and subsequent protein release. In these constructs, the anti-sense ssrA oligonucleotide sequence may be added to prevent addition of a C terminal protease site in the 3' untranslated region that follows.

30 In a fourth aspect the present invention provides a kit for generating a replicable mRNA transcript which includes a DNA construct according to the second aspect of the present invention.

In a preferred embodiment the kit includes at least one other additional component selected from

35 (i) an RNA-directed RNA polymerase, preferably Q β replicase, or a DNA or RNA template for an RNA-directed RNA polymerase;

- (ii) a cell free translation system;
- (iii) a DNA directed RNA polymerase, preferably a bacteriophage polymerase;
- (iv) ribonucleoside triphosphates; and
- 5 (v) restriction enzymes.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group

10 of elements or integers.

BRIEF DESCRIPTION OF THE FIGURES

- Figure 1: Affinity maturation cycle for a) phage display and b) ribosome display in the continuous *in-vitro* evolution (CIVE) process.
- 15 Figure 2: Schematic representation of an expression unit containing a gene of interest (nucleotide sequence) for CIVE. The expression unit comprises a gene of interest with upstream ribosome binding site (RBS) and translational initiation site (ATG) along with a transcriptional initiation sequence (T7 promoter). The construct also comprises a downstream spacer sequence.
- 20 Figure 3: Schematic representation of the CIVE method showing the continuous cycling nature of *in vitro* affinity maturation. The method enables the *in vitro* production of complex libraries of mutants which are continuously evolving (mutating) and from which a desired gene may be selected; the mRNA molecules in the preferred transcription/translation system of the present invention are in a
- 25 continuous cyclic process of re[plication/mutation/translation leading to continuous *in vitro* evolution (CIVE).
- Figure 4: Representation of a reaction vessel suitable for the CIVE process.
- Figure 5: Nucleotide sequences of: a) the first constant light region of mouse monoclonal antibody 1C3; b) the third constant heavy region of the human IgM
- 30 antibody; c) the anti glycoporphin (1C3) scFv; d) the anti-HepatitisB surface antigen (4C2) scFv.
- Figure 6: DNA sequence of the plasmid pBRT7Qbeta containing a cDNA copy of the Q β bacteriophage genome.
- Figure 7: Schematic representation of the plasmids (a) pGC038CL (containing the
- 35 anti-glycoporphin scFv (1C3) and the mouse constant light region) and (b) pGC_CH (containing the human constant heavy region), which were used for the PCR

synthesis of template used for *in vitro* transcription and translation. These plasmids were used to supply downstream spacer sequences. In most cases, genes of interest were cloned into SfiI and NotI sites of pGC_CH.

Figure 8: Sequences of RNA fragments that form stem loop structures

- 5 **Figure 9:** Eukaryotic expression vector pcDNA3.1 for expression of Q β replicase or Hepatitis C virus RNA dependent RNA polymerase in the rabbit reticulocyte coupled transcription/translation system.

Figure 10: DNA sequence of the Hepatitis C virus RNA dependent RNA polymerase.

- 10 **Figure 11:** DNA sequences of oligonucleotides used as primers in PCR reactions to generate template DNA for *in vitro* coupled transcription/translation reactions. Nucleotide sequences of oligonucleotides used for both the generation of templates and the recovery of products after panning. Sequences are numbered and are written 5' to 3'.

- 15 **Figure 12:** Expression of the Q β replicase in the rabbit reticulocyte coupled transcription/translation system

Figure 13: Effect of Q β replicase on coupled transcription/translation of anti GlyA 1C3 protein synthesis.

Figure 14: Effect of including Q β replicase in coupled transcription and translation;

- 20 Table of mutations in the sequences of selected mutants. This figure shows the positions and type of mutations found in 280 nucleotides of sequence from 6 random clones. These had been recovered from pannings of the anti-GlyA scFv against GlyA coated Dynabeads after transcription and translation either in the absence of Q β replicase, in the presence of purified Q β or in the presence of
- 25 plasmid pCDNAQ β . In the "Mutation Found" column; "None" means that no mutations were found; Mutations are shown in the form AxB where A is the wild type nucleotide, x is the position number within the sequence (as presented in Figure 5c) and B is the mutated nucleotide observed.

- 30 **Figure 15:** Replication of anti glycoporphin scFv transcripts by Q β replicase in the coupled transcription/translation rabbit reticulocyte system: densitometer scanning.

Figure 16: DNA sequence analysis of replication and mutation of anti glycoporphin scFv and anti Hepatitis B scFv by Q β replicase from T7 polymerase transcripts.

Figure 17: Vector containing the Hepatitis C RNA dependent RNA polymerase.

- 35 **Figure 18:** Effect of Hepatitis C RNA dependent RNA polymerase expressed in the coupled transcription/translation system on replication of anti GlyA 1C3 scFv RNA.

Agarose gel electrophoresis of the RT-PCR products stained with ethidium bromide and scanned.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

5 In a preferred aspect of the present invention, the system for continuous one-step evolution of proteins comprises the following components:

The expression unit

A preferred expression unit for use in the present invention is depicted in Figure 2. This expression unit comprises 3' and 5' untranslated regions with in the
10 5' untranslated region a control element such as the T7 or SP6 promoter to promote transcription of the DNA into mRNA. The consensus DNA sequences are specific for their polymerases; the T7 promoter sequence for T7 RNA polymerase is: TAATACGACTCACTATAGGGAGA. The T7 promoter sequence may act as an RNA dependent RNA polymerase binding sequence (ie. it may act as a binding sequence
15 for Q β replicase). Preferably, however, the construct includes a stemloop structure for the binding of Q β replicase, located in the 5' untranslated region 3' to the promoter site. Preferably, a second stemloop structure is included downstream of the coding sequence, preferably about 1 kb 3' of translation termination site of the expression unit. The preferred sequence of the stemloop structure is:
20 GGGACACGAAAGCCCCAGGAACCUUUCG.

The ribosome binding site is the next region downstream of the promoter. Any of several ribosome binding be used in this position. Prokaryotic and eukaryotic ribosome binding sequences may be incorporated depending on whether a eukaryotic or prokaryotic coupled system is being used. One preferred prokaryotic
25 binding site is that of the MS2 virus. The translation initiation sequence ATG is preferably used and codes for the amino acid methionine; this is the start of *in vitro* translation.

The gene (nucleotide sequence) of interest.

It will be apparent to those skilled in the art that the gene of interest can be
30 attached to the untranslated regions by any of the standard genetic techniques. The gene of interest may include any nucleotide sequence with an open reading frame (no stop codons) up to the 3' end of the gene and for the purposes of this invention the end of the anchor (spacing) sequence.

In a preferred embodiment the gene(s) of interest is a nucleotide sequence
35 coding for i) a library of target binding proteins or ii) a single target binding protein, where the target may include any of protein, DNA, cell surface molecules,

receptors, antibodies, hormones, viruses or other molecules or complexes or derivatives thereof. A nucleotide sequence coding for an anchor domain may be fused 3' and in frame with the gene of interest. The anchor domain may be any of a series of polypeptide sequences sufficiently long to space the protein translated from the gene of interest a sufficient distance from the ribosome to allow correct folding of the molecule and accessibility to its cognate binding partner. In a preferred embodiment the anchor is the sequence coding for the octapeptide "FLAG" epitope: DYKDDDDK or any of the human or murine antibody constant domains. Preferably, the anchor is the constant domain from a mouse monoclonal antibody, such as constant domain 1C3 (see Figure 5a). A further preferred anchor is the constant region from a human IgM antibody (see Figure 5b).

The anchor sequence may be followed by a translation termination (stop) nucleotide sequence e.g. TAA or TAG. However, in some constructions it could be envisaged that no stop codons should be present to prevent recognition by release factors and subsequent protein release. In these, the anti-sense ssrA oligonucleotide sequence is added to prevent addition of a C terminal protease site in the 3' untranslated region that follows. The addition of sparsomycin, other similar compounds or a reduction in temperature also prevents release of the ribosome from the mRNA and *de novo* synthesised protein.

20

The expression system

Transcription/replication /mutation for the expression unit may be achieved by use of a rabbit reticulocyte lysate system (He and Taussig, 1997) or an *E.coli* S-30 transcription translation mix (Mattheakis et al., 1994; Zubay, 1973). For example a DNA expression unit (detailed above) with a T7 promoter is treated with T7 RNA polymerase according to the manufacturers instructions. The resulting RNA library reflects the diversity of the encoded genes. RNA dependent-RNA polymerases added for replication and mutation can be supplied either as purified enzyme or alternatively encoded as a distinct expression unit in a plasmid under control of a promoter such as T7 or SP6. The preferred enzyme is Q β replicase although any enzyme with similar characteristics may be used. This step provides the increase in complexity of the library through mutation by the Q β replicase. For mRNA synthesis in eukaryotic cells the mRNA is preferably capped which is achieved by adding an excess of diguanosine triphosphate; however, the rabbit reticulocyte system from the commercial suppliers Promega and Novagen have components in the system to make the addition of capping compounds unnecessary. The

35

transcription/translation mix or coupled system may be extracted from any cell, those most commonly used are wheat germ, mammalian cells such as HeLa cells *E.coli* and rabbit reticulocytes. The coupled transcription translation system may be extracted from the *E.coli* mutator cells MUTD5-FIT (Irving et al., 1996) which
5 bear a mutated DNAQ gene and therefore allow further random mutations introduced into DNA during replication as a result of proofreading errors. One preferred transcription/translation mix is the rabbit reticulocyte lysate. Addition of GSSG to the coupled system enhances correct folding of displayed proteins and therefore enhances subsequent binding and selection to counter-receptors or
10 antigens.

Mutation by Q β replicase

The Q β replicase is included in the system for the replication and production of high levels of mRNA incorporating random mutations (see Figure 3). Multiple copies of a single-stranded RNA template is replicated with mutations by the Q β
15 replicase into its single stranded complement; however, both strands are equally efficient as template under isothermal conditions.

Teaching in the art indicates that the complex and stable secondary and tertiary structures present in full length RNA from phages such as Q β limit the access of ribosomes to the protein initiation sites. However, we have found that
20 smaller RNA sequences are suitable for binding of replicases and therefore may be used instead of full length templates. Preferred sequences are small synthetic RNA sequences known as pseudoknots (Brown and Gold 1995;1996) which are compatible with amplification by Q β replicase. In the context of the present invention, the use of pseudoknots can overcome the problems of ribosome access to
25 the protein initiation sites whilst maintaining the binding sites necessary and sufficient for the Q β replicase amplification of the RNA and sequences fused thereto.

Translation and Ribosome display

Several *in vitro* translation methods are known which may be either
30 eukaryotic such as rabbit reticulocyte lysate and wheatgerm, or prokaryotic such as *E.coli*. These are available commercially or can be generated by well known published methods. Translation of the mutated mRNAs produces a library of protein molecules, preferably attached to the ribosome in a ternary ribosome complex which includes the encoding specific mRNA for the de novo synthesised
35 protein (Mattheakis et al., 1994). Several methods are known to prevent dissociation of the mRNA from the protein and ribosome. For example,

sparsomycin or similar compounds may be added; sparsomycin inhibits peptidyl transferase in all organisms studied and may act by formation of an inert complex with the ribosome (Ghee et al., 1996). Maintaining high concentrations of magnesium salts and lowering GTP levels may also contribute to maintaining the ribosome/mRNA/protein complex; in conjunction with the structure of the expression unit detailed above. A preferred means to maintain the ternary ribosome complex is the omission of the translation stop codon at end of the coding sequence.

In addition, there are preferred requirements for the correct folding of the molecules in the two systems. For prokaryotes protein disulphide isomerase (PDI) and chaperones may be used as well as a C terminal anchor domain to ensure the correct folding. The latter is required as prokaryotic proteins are released from the ribosomes prior to folding (Ryabova et al., 1997) and therefore in situations in which the peptide is anchored to the ribosome the entire protein needs to be spaced from the ribosome. In contrast to this in eukaryotic systems the protein is folded as it is synthesised and has no requirement for the prokaryote PDI and chaperones to be added; however, we have found that addition of a specific range of GSSG concentrations is beneficial to the library selection by the enhanced display of correctly folded proteins on the ternary ribosome complexes.

Selection and competitive binding

Successive rounds of RNA replication produce libraries of RNA molecules which on translation produce libraries of proteins. A target molecule-bound matrix (for example antigen-coated Dynabeads) may be added to the reaction to capture ternary ribosome complexes. The individual members in the library compete for the antigen immobilised on the matrix (Dynabeads). Molecules with a higher affinity will displace lower affinity molecules. At the completion of the process the complexes [mRNA/ribosomes/protein] attached to matrix (Dynabeads) may be recovered, cDNA may be synthesised from the mRNA in the complex and cloned into a vector suitable for high-level expression from the encoded gene sequence.

A recycling flow system (Spirin et al., 1988) may be applied to this Continuous in vitro Evolution (CIVE) system using a thermostated chamber to ensure supply of substrates (including ribosomes) and reagents and removal of non-essential products. All processes of CIVE may take place within this chamber including: coupled transcription and translation, mutating replication, display of the *de novo* synthesised protein on the surface of the ternary ribosome complex and

competitive binding of the displayed proteins on the ternary ribosome complex to antigen to select those with the highest affinity binding (Figure 4). The unbound reagents, products and displayed proteins are removed by flushing with washing buffer and the bound ternary ribosome complexes are dissociated by increasing the temperature and omitting the magnesium from the buffer. This is followed with the addition of all the reagents necessary to carry out all the above steps except the washing buffer steps. Methods are available to prevent dissociation of the mRNA from the protein and ribosome such as the addition of sparsomycin or similar compounds, maintaining specific concentrations of magnesium salts and lowering GTP levels may also contribute to maintaining the ribosome/mRNA/protein complex as well as reducing the reaction temperature or omitting translational stop codons. By using vessels whose temperatures are controlled combined with a continuous flow capability, mRNAs from selected ribosomes may be dissociated from the ribosomes and further replicated, mutated and translated as the concentration of reagents important for the maintenance of the ribosome/mRNA/protein complex such as sparsomycin, Mg etc are varied. Figure 4 depicts the design of a such a device.

The present invention will now be more fully described with reference to the following non-limiting Examples.

Example 1

Recombinant Q β replicase: Expression and purification

Cloning and expression

The Q β replicase coding sequence was amplified by PCR from the plasmid pBRT7Q β , a pBR322 based construction (briefly described in Barrera et al., 1993) that was designed to allow the preparation of infectious RNA by transcription using T7 RNA polymerase *in vitro*; being a cDNA copy of the RNA genome of phage Q β . The sequence of pBRT7Q β is shown in Figure 6. Nucleotide no.1 is the first nucleotide of the Q β replicase sense strand. The oligonucleotides used as primers to amplify the Q β replicase encoded sites for restriction enzyme digestion by the enzymes *EcoRI* and *Not I* and the sequences are shown in Figure 11.

The PCR products were purified using any one of the commercial products available for this purpose (for example Bresatec). The purified DNA was cloned into the *EcoRI* and *NotI* sites of the vector pGC (Figure 7a) using standard molecular biology techniques. The vector pGC and expression of recombinant protein therefrom has been described in the literature and is incorporated herein by

reference (Coia et al., 1996). The process of the PCR amplification and cloning of the Q β replicase gene into vectors and transformation into *E.coli* for expression of the enzyme will be known to those skilled in the art as will be the expression of the Q β replicase gene in pGC which was induced by adding 1mM

- 5 isopropylthiogalatoside (IPTG) to the culture medium.

Expression and purification of the Q β replicase gene in the pBR322 based vector with the promoter PL was performed as detailed below. The rep14 Billeter strain was supplied by Christof Biebricher, Max Planck, Gottingen. The *E.coli* strain was grown in a 20 l fermentor in 2% nutrient broth, 1.5% yeast extract, 0.5%
10 NaCl, 0.4% glycerol, 100mg/l ampicillin with good aeration at 30°C to an optical density of 2 (660nm). After raising the temperature to 37°C, aeration was continued for 5 h. The cells were chilled on ice and harvested by centrifugation (yielding about 180 g wet cell mass).

15 Purification of Q β replicase

Buffer A: 0.05M Tris.HCl-buffer (pH 7.8), 1mM mercaptoethanol, 20% v/v glycerol,
100 mg/l ampicillin.

Buffer B: 0.05M HEPES.Na-buffer (pH 7.0), 1mM mercaptoethanol, 20% v/v
glycerol.

20

50g harvested *E.coli* were homogenized with 100ml. 0.05M Tris.HCl buffer (pH 8.7) 1mM mercaptoethanol in a high-speed blender. Lysozyme and EDTA were added to final concentrations of 100 μ g/ml and 0.5mM, respectively, and the solution was gently stirred at 0°C for 30 min. 12ml 8% Na deoxycholate, 0.24ml

- 25 phenylsulfonylfluoride (20mg/ml in propanol-2), 0.15ml Bacitracine (10mg/ml), 0.15ml 0.1M benzamidine, 3.3ml 10% Triton-X-100 were added and the solution adjusted with MgCl₂ to 10mM final concentration. The high viscosity was reduced by blending at high speed. Solid NaCl was added to a final concentration of 0.5M and 4.8ml 0.3% polyethyleneimine (pH 8) was added with stirring. After stirring
30 for 20 min at 0°C the suspension was centrifuged for 30 min at 10,000 rpm (GSA rotor). After dilution of the supernatant with 5 volumes Tris.HCl buffer (pH 8.7) 1mM mercaptoethanol, 100ml DEAE cellulose slurry (Whatman DE52, equilibrated with buffer A) was added and slowly stirred at 0°C for 20 min. After 40 min incubation without stirring, the supernatant was decanted from the sediment and
35 discarded. The sediment was suspended in buffer A, poured into a glass column of 1cm diameter, washed with 400ml Tris.HCl buffer (pH 8.7) 1mM mercaptoethanol,

and eluted with 250ml buffer A + 180mM NaCl; fractions were collected. The fractions were assayed for the presence of Q β replicase using the following binding assay.

5 Enzyme location assay: binding of biotinylated RNA to Q β replicase

This is a non-radioactive assay developed to detect replication enzymes which relies on biotin-labelled RNA bound to enzyme being retained on positively charged membranes: whereas, free biotin-labelled RNA under the same conditions is not retained on the membrane. DNA and RNA were labelled with psoralen-biotin
10 (Ambion) according to the manufacturers instructions. The labelled RNA was then added to the column eluate (sample fractions) as indicated in the assay below to detect the location of Q β replicase.

The following was mixed in an Eppendorf tube:

- 15 10 μ l column eluate fractions
 10 μ l 0.5M Tris HCl (pH 7.4) containing 120mM MgCl₂
 10 μ l 2mM ATP
 10 μ l 5mM ATP
 10 μ l ~100ng/ml psoralen-biotin labelled probe RNA
20 50 μ l water

The reaction mix was incubated at 37°C for 1min.

The reaction mixtures were dot blotted onto nylon membrane. e.g. hybond N, (only RNA or DNA bound to the enzyme Q β replicase will be retained on the membrane),
25 washed with the 50mM Tris HCl pH 7.4 containing 12mM MgCl₂, UV cross linked onto the nylon membrane in the Stratalinker on the automatic setting. The BrightStar Biodetect kit was used for the detection of the biotinylated nucleic acid attached to the nylon membrane. Figure 12 shows the assay of the eluted fractions from the DE52 column.

30 The active fractions were pooled, diluted with one volume buffer A and applied to a 35ml column of DEAE-Sepharose FF, equilibrated to buffer A + 0.1M NaCl. The enzyme was eluted with a linear gradient of 0.1-0.4M NaCl in buffer A. The active fractions were pooled, the enzyme precipitated by addition of solid (NH₄)₂SO₄ (39g / 100ml solution), collected by centrifugation and dissolved in 4ml
35 buffer B.

The enzyme was diluted until the conductivity was less than that of buffer B + 0.2M NaCl and applied to a 100ml column of Fractogel EMD SO3 equilibrated with buffer B. and eluted with a linear gradient (2 times 500ml) of 0.2--0.8~M NaCl in buffer B. The active peaks, eluting at about 0.65M NaCl, were pooled,
5 precipitated with solid $(\text{NH}_4)_2\text{SO}_4$ (39g / 100ml solution), collected by centrifugation, and dissolved in 10ml buffer A + 50% glycerol. The solution was stored at -80°C.

The following steps were performed at small scale according to Sumper & Luce (1975). 4 mg Q β replicase were applied to a 1.6 x 14.5cm column of QAE-Sephadex~A-25 equilibrated with buffer A (diluted or dialysed to remove salt), and
10 eluted with a 2x200ml gradient of 0.05--0.25M NaCl in buffer A. The two clearly separated peaks of core and holoenzyme were pooled, diluted 1:1 with buffer A and applied to QAE-Sephadex columns, 2ml for core, 6ml for holo replicase, respectively, washed with buffer A + 50% glycerol, and the replicase was eluted in
15 concentrated form with buffer A + 50% glycerol + 0.2 M $(\text{NH}_4)_2\text{SO}_4$. The active fractions were stored at -80°C. Care was taken to avoid contamination of the equipment with RNA.

Example 2

20 Cloning of Q β replicase into the eukaryotic expression vector pCDNA3.1

Q β replicase coding sequence was cloned into the eukaryotic expression vector pCDNA 3.1 (Figure 9) to produce the vector named pCDNAQB. This vector was used for the expression of Q β replicase *in situ* in the coupled
25 transcription/translation system and concomitant replication/mutation of target RNA. Sequence of oligonucleotides used as primers in PCR amplification of Q β replicase for cloning into the *EcoRI* and *NotI* restriction sites in the eukaryotic expression vector pCDNA3.1 were:

5352 5'TCTGCAGAATTCGCCGCCACCATGTCTAAGACAGCATCTTCG

5350 5'TTTATAATCTGCGGCCGCTTACGCCTCGTGTAGAGACGC

30 The coding sequence for the Q β replicase b subunit was cloned into the pCDNA3.1 by standard molecular biology techniques (Sambrook et al., 1989). The cloned sequence was confirmed by DNA sequence analysis. Expression of the Q β replicase in the rabbit reticulocyte coupled transcription/translation system was followed by the detection of biotinylated lysine (TRANSCEND, Promega)
35 incorporated into the de novo synthesised Q β replicase in the standard transcription/translation reaction as suggested by the commercial suppliers of the

coupled transcription translation kits (Promega and Novagen) and the supplier of Transcend (Promega). At the completion of the incubation step of the coupled reaction, 20 μ l of the reaction was heated to 90°C with 2ml of 10X SDS sample buffer and the samples subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). This was followed by Western blotting and the *de novo* synthesised biotinylated Q β replicase bands detected with TRANSCEND kit detection reagents. The results of this expression are shown in the gel scans of Figure 12 where it can be seen that Q β replicase has been synthesised shown by the biotinylated band at the correct size on the gel.

We then undertook coupled Transcription/translation reactions with the 1C3 template (example 3) but also expressing the Q β replicase from pcDNA3.1 in the same reaction. The Q β replicase synthesised *in situ* from the expression vector pCDNAQ β resulted in the increased synthesis of the 1C3 scFv in the coupled system in the presence of 0.5mM manganese chloride; measured by incorporation of biotinylated lysine (Figure 12b) as described above. The presence of the manganese chloride has previously been shown to relax the dependence of the Q β replication activity on transcription/translation factors.

Example 3

Construction by PCR of DNA templates for transcription.

DNA sequences were amplified by standard and well-described techniques (Polymerase Chain Reaction [PCR] with specifically designed oligonucleotide primers, splice overlap extension, restriction enzyme digests etc) using either *Taq*, *Tth*, *Tfl*, *Pwo* or *Pfu* polymerase according to the supplier's instructions using either an FTS-1 thermal sequencer (Corbett Research), a PE2400 (PerkinElmer) or a Robocycler gradient 96 (Stratagene). A list of oligonucleotide primers used is given in Figure 11. Products were gel purified using BresaClean (Bresa) or used directly in coupled transcription and translation reactions.

DNA sequences were amplified from starting templates which had been cloned into either vector pGC038CL (Figure 7a) or pGC_CH (Figure 7b) which provided an extension to the 3' terminus of the construct. This extension was either a constant region from a mouse monoclonal (1C3; Sequence Figure 5a) or a constant region from a human IgM antibody (Sequence Fig. 5b). Forward (sense) primers (N5266 for the anti-GlyA scFv; N5517 or N5384, N5344 and N5343 for the anti-HepB scFv) used for amplification provided a transcriptional initiation site as well as a translational initiation site and ribosome binding site. Reverse (antisense)

primers (N5267 for the mouse constant region; N5385 for the human constant region) did not contain stop codons which allows the mRNA-ribosome-protein complex to remain associated. Both forward and reverse primers provided restriction enzyme sites (specifically SfiI and NotI, respectively) which enabled
5 cloning of generated fragments.

Any of several promoter sequences for DNA dependent RNA polymerase can be used to direct transcription; however, the following sequences were the two preferred (these include translational initiation sequences; see below):

- a) GCGCGAATACGACTCACTATAGAGGGACAAACCGCCATGGCC
10 b) GCAGCTAATACGACTCACTATAGGAACAGACCACCATGGCC

These sequences have directed transcription of T7 DNA dependent RNA polymerase to produce RNA transcripts in two alternative formats of coupled transcription/translation systems.

Sequences encoding ribosome binding sites are known and have been
15 included in the template upstream of the any one of the sequences of molecules of interest for ribosome display encoding either the scFv binding to glycophorin (1C3; Figure 5c) or the scFv binding hepatitis B surface antigen (4C2; Figure 5d). The same sequences have been included in the template upstream of any other sequences of interest for ribosome display (eg CTLA-4-based library sequences).

20

Example 4

Coupled transcription/translation and ribosome display in rabbit reticulocyte lysate cell free system.

Transcription and translation was carried out in Siliconized Rnase-free 0.5ml
25 tubes (Ambion) using the TNT T7 coupled transcription/translation system (Promega) containing 0.5mM magnesium acetate, 0.02mM methionine and 3mM oxidized glutathione (GSSG) (see Example 6, below) and the mixture was incubated at 60°C for 90 min. In some reactions up to 10mM reduced glutathione was also added. In reactions containing Q β polymerase, the mixture also contained
30 manganese chloride to a final concentration of 0.5mM. After transcription and translation, the mixture was diluted with PBS and treated with DNaseI to remove any remaining starting DNA template. This was achieved by the addition of 40mM Tris (pH 7.5), 6mM MgCl₂, 10mM NaCl and DNase I (Promega), followed by incubation at 30°C for a further 20min.

Example 5

Selecti n of ribosome ternary complex displayed prot ins against antigens using Dynabeads

Tosylactivated Magnetic beads (Dyna) were coupled to GlycophorinA (GlyA; Sigma), HepatitisB Surface Antigen (HepB SA; BiosPacific, Emeryville, CA USA) or bovine serum albumin (BSA; Sigma) according to manufacturer's instructions. Where Streptavidin magnetic beads were used, these were coupled (according to manufacturer's instructions) to antigens (as shown above) which had been biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Pierce) according to manufacturer's instructions.

In order to select specifically binding mRNA-ribosome-protein complexes, 2-3 μ l of antigen coupled (tosylactivated or streptavidin coated) magnetic beads were added to the final translation mixture and placed on a plate shaker (Raytek Instruments) at room temperature for 90 min with gentle shaking to prevent settling of the beads. The beads were recovered using a magnetic particle concentrator (Dyna) and these were washed three times with cold phosphate buffered saline (PBS) pH 7.4 containing 1% Tween and 5mM magnesium acetate. The beads were then washed once with cold sterile water and finally resuspended in 10 μ l of sterile water.

For the synthesis of cDNA from selected complexes, 2 μ l of the final bead suspension was used in an RT-PCR reaction using either the Access RT-PCR system (Promega) or the Titan One-tube RT-PCR system (Boehringer Mannheim) according to manufacturer's instructions. The primers used for this reaction included the original forward (sense) primer (used to generate the starting template DNA primers; N5266 for the anti-GlyA scFv; N5517 or N5384, N5344 and N5343 for the anti-HepB scFv) and a negative (antisense) primer which was upstream of the original primer (N5268 and N5269 for mouse constant region constructs; N5386 and N5387 for human constant region constructs). In some cases, shorter primers (N5941 and N5942 for the anti-GlyA scFv-constant light region construct) were used to recover panned RNA templates.

For further cycles of selection, this DNA was gel purified (in some cases, simply diluted) and incorporated into in a further PCR using the forward and reverse primers which had been present in the original PCR to generate the starting DNA template. This new template could then be used in further selections as described above since it contained the appropriate initiation sites and is of the same length as the template in the first selection.

In order to show that the method described above can be used to select specific molecules, a single chain Fv (scFv) fused to a mouse constant light chain region which specifically binds to GlyA was amplified using primers which would allow the addition of a T7 transcriptional initiation site and a ribosome binding site.

5 This template (T7-scFv) was used in a coupled transcription/translation reaction as described above and then split into three and mixed with either HepB SA, GlyA or BSA coupled magnetic beads. The beads were washed (as described above) and recovered mRNA-ribosome-protein complexes were used to synthesize cDNA. The results of this experiment showed the presence of a product of the correct size in
10 each lane. The non-specific binding observed in the HepB SA and BSA lanes is probably due to aggregation of products synthesized during translation. It has been observed by others that only a proportion of products synthesized using the reticulocyte lysate are in a properly folded and active form. This problem was addressed in Example 6 below.

15 The GlyA specific product from this experiment was gel purified and re-amplified by PCR in order to synthesize more template for a further round of selection. A second round of panning showed predominantly a specific product in the sample probed with GlyA coupled magnetic beads. This showed that by the second round of selection, the products recovered were specific for GlyA.

20

Example 6

Effect of adding oxidized and/or reduced glutathione

In an attempt to induce a higher proportion of correctly folded products during *in vitro* transcription and translation, various concentrations of either
25 reduced or oxidized glutathione were added to the reaction mixture. The template used for these reactions was the anti-GlyA T7-scFv (as described above) and selections were performed using GlyA coupled magnetic beads. This experiment showed that the amount of recovered product increased with increasing concentrations of oxidized glutathione up to 5mM. A further increase to 10mM
30 had a detrimental effect on the yield of recovered product. A concentration of around 2mM oxidized glutathione was included in most transcriptions and translations.

Later results revealed that a further addition of 5mM and 10mM reduced glutathione to the reaction already containing 2mM oxidized glutathione showed
35 that the addition of 5mM glutathione appeared to allow better folding of the displayed anti-GlyA scFv leading to an increased amount of recovered product from

the GlyA panning over the control pannings. Further decreasing the concentration of reduced glutathione to 0.5mM showed similar effects.

Example 7

5 Display of mutation v-domain (CTLA-4) library on ribosomes

In order to show that ribosome display could be used to select binding elements from a polypeptide library, a library of CTLA4 mutants was ligated into plasmid pGC_CH (Figure 7b) which allowed the addition of a constant heavy domain and this library was then amplified by PCR using primers N5659 and N5385
10 (Figure 11). Primer N5659 was used to add the necessary upstream transcriptional and translational initiation sequences. This PCR DNA was then used as template for transcription and translation in a coupled cell free translation system using the methods described in Example 4. To demonstrate binding of mutant CTLA
15 ribosome complexes, panning was performed using Hepatitis B surface antigen (HBSA), GlycophorinA (GlyA) and Bovine Serum Albumin (BSA) coated Dynabeads. RNA attached to bound complexes was then recovered by RT-PCR. The methods used for panning, selection and recovery was as described previously (Example 5).

Products corresponding approximately to the size of CTLA4 based mutants
20 were recovered and showed that the CTLA4 library contained DNA encoding proteins which specifically bind HBSA, GlyA and BSA. These products were cloned into the vector pGC_CH (Figure 7b) for DNA sequencing and expression of soluble products. Sequencing using standard methods (BigDye Terminator Cycle Sequencing; PE Applied Biosystems CA) showed that CTLA4-based specific inserts
25 were present. Furthermore, expression analyses using ELISA showed that specifically reactive proteins were being expressed by the recombinant cultures. In these assays, recombinants which had been isolated by panning using GlyA-coated Dynabeads and screened by ELISA using GlyA-coated plates, gave stronger signals than similarly tested recombinants which had been isolated by panning using BSA-coated Dynabeads.
30

Example 8

Effect of including Q β replicase in coupled transcription and translation.

In an attempt to both increase the yield of products, and increase the rate of
35 mutagenesis in products during in vitro translation, Q β replicase (in either of two forms) were added to the reaction mixture. The replicase was included as either a

purified Q β replicase protein or as a gene template under the control of a T7 transcriptional promoter (pCDNAQ β) which could be simultaneously synthesized during the coupled transcription/translation reaction. The template used for this reaction was again the anti-GlyA T7-scFv (as described above) and selections were performed using GlyA coupled magnetic beads. These experiments showed that the amount of recovered GlyA reactive product increased (over the no Q β replicase control) with the addition of purified Q β replicase and, to a lesser extent, with the addition of Q β replicase-encoding genomic template (pCDNAQ β).

In order to determine whether mutations had been inserted into the scFv sequence, the main product from each lane was gel isolated and purified. The DNA was digested with *Sfi*I and *Not*I and ligated into similarly digested pGC vector and transformed into *E. coli* using standard protocols. DNA was isolated from recombinants from each series and six random clones from each series were subjected to DNA sequencing using standard methods (BigDye Terminator Cycle Sequencing; PE Applied Biosystems CA). Approximately 280 bases were sequenced from each clone and Figure 14 shows the number and the position of mutations in these sequences. This experiment showed the introduction of an increased number of mutations after transcription and translation in the presence of Q β replicase (in either of the forms used).

Example 9

Addition of artificial Q β sequences.

In an attempt to increase the efficiency of Q β replicase activity, specific Q β binding sites were added to both the 5' and 3' ends of the anti-GlyA T7-scFv template by PCR. This new template (amplified with primers N5904 and N5910 [sense] and N5909 [anti-sense]; Figure 11) was used in a coupled transcription/translation reaction which included Q β replicase as either a purified Q β replicase protein or as a gene template under the control of a T7 transcriptional promoter which could be simultaneously synthesized during the coupled transcription/translation reaction. Selections were performed using HepB, GlyA or BSA coupled magnetic beads and products recovered after RT-PCR. The presence of artificial Q β stemloop sequences (i) did not have an adverse effect on coupled transcription, translation and selection and (ii) in most cases increased the amount of products recovered by RT-PCR after selection.

Example 10

Replication of anti glycophorin scFv transcripts by Q β replicase in the coupled transcription/translation rabbit reticulocyte system.

The T7-1C3 and T7-4C2 scFv templates for ribosome display were
5 constructed as described in example 3 and subjected to coupled
transcription/translation, under the following conditions. Standard coupled
transcription/translation reactions were modified by the addition of Q β replicase
(purified as detailed in example 1). In a standard 20 μ l reaction 1ml of 20 μ g/ml
10 enzyme was added. Previously we have compared the effect of Q β replicase
concentration on replication of anti GlyA 1C3 scFv and anti Hepb 4C2 scFv in th
coupled system and observed that 1ml of this sample provided the optimum
replication. Manganese chloride was added to a final concentration of 0.5mM as
this has been shown in published reports to decrease the requirement for
transcription/translation factors. Reactions were allowed to continue for 2 hrs at
15 37°C. The replicated transcripts were analysed by RT-PCR after removing DNA
template by DNAase I digestion in 40mM Tris-HCl pH7.5, 6mM MgCl₂, 10mM NaCl
at 30°C for 20 mins. Standard phenol extraction was used to remove DNAaseI and
other proteins. Samples were ethanol precipitated and the RNA precipitate
dissolved in RNAase-free water. The RNA was assayed by RT-PCR using primers
20 specific for each template, see example 3, and the PCR products (DNA) compared
by agarose gel electrophoresis. The DNA bands were visualised by staining with
ethidium bromide. The agarose gel was subjected to densitometry by scanning the
digitised image with the gel-pro analyzer commercial software. Figure 13 shows the
densitometer traces of the agarose gel from which it can be seen that in the sample
25 containing the purified Q β replicase there is an increase in the amount of templat
produced.

Example 11

**Replication and mutation of anti glycophorin scFv and anti Hepatitis B scFv by Q β
30 replicase from T7 polymerase transcripts; Q β replicase mutates transcripts during
RNA dependent RNA replication.**

Coupled transcription/translation reactions as detailed in previous examples
were supplemented with Q β replicase purified enzyme to replicate and mutate the
T7 DNA dependent RNA polymerase transcribed anti GlyA 1C3 scFv RNA.
35 Following the transcription/replication/mutation/translation incubation, the sample
was treated with DNAaseI and this enzyme removed as detailed in example 10. The

- purified RNA was then used as the template for RT-PCR reactions with anti GlyA 1C3 scFv -specific primers in the reaction as detailed in example 3. The thermostable polymerases used in these reactions were one of the high fidelity *vent.* *pfu* polymerase enzymes used in accordance with the manufacturers instructions.
- 5 The PCR reaction products were purified with one of the commercially available kits as noted before and the purified DNA ligated into the commercially available plasmid pCRscript and transformed into competent *E.coli* XL1Blue cells using standard molecular biology techniques. The transformation reactions were plated onto YT-agar plates containing X-gal. After overnight incubation white colonies
- 10 (*E.coli* with plasmids containing DNA inserts in the multi-cloning site) were picked and grown overnight at 37°C in 5 ml of YT broth containing 100µg/ml ampicillin. DNA was extracted from each of the cultures with the commercial kit (Qiagen) according to the manufacturer's instructions. The purified DNA was analysed by DNA sequencing: the sequencing results are displayed in Figure 16. This table
- 15 shows mutations in a random sample of sequences representing a minute sampling of mutations and sequence variation in the whole Q β replicase replication/mutation reactions.

Example 12

20 Predicted secondary structure of template RNA

- The RNA sequences and putative secondary structures preferred by Q β replicase for its RNA templates have been reported (Zamora et al., 1995). To determine whether these or related preferential structures exist in the templates for the continuous in vitro evolution the upstream untranslated sequences; T7
- 25 promoter sequences. the sequences encoding the 1C3 gene, the constant light anchor region gene. the anti hepb 4C2 scFv gene and the IgM human constant heavy anchor region gene were analysed with the Mfold program (Zucker et al , 1991) and compared to the Q β replicase preferred structures (as shown in Figure 8). From this comparison it can be seen that the 1C3 scFv has been identified to have
- 30 internal RNA secondary structure mimicing the M site structure of Q β replicase. as does the CL anchor region and shows similarity to the preferred synthetic sequence reported by Zamora et al., 1995. This may explain the preferred replication of the anti GlyA 1C3 scFv CL template to that of the anti Hepb 4C2 scFVCH3 by Q β replicase (see example 3). Therefore the CL region gene is proposed as an anchor
- 35 region for displayed molecules for coupled transcription/translation display and

any mutagenesis as the RNA encoding this region promotes and enhances Q β replicase replication and associated mutation of this region and its genetic fusions.

Example 13

5 Expression protocol for pLysN-NS5B (83kDa, pI~9.05)

pLysN-NS5B is a bacterial (cytoplasmic) expression vector with a T7 promoter. NS5B is the non-structural HepC RNA-dependent RNA-polymerase. NS5B is fused to a LysN moiety at its N terminus which are separated by a Gly-Ser-Gly-Ser-Gly linker. 10 His residues and followed by a Asp-Asp-Asp-Asp-Lys linker
10 (GSGSGH10D4K).

This plasmid was transformed into *E.coli* strain HMS174(DE3)pLysS and grown on 1YT/Amp₁₀₀ $\mu\text{g/ml}$ /Chloramphenicol₃₄ $\mu\text{g/ml}$ agar plates at 37°C. A single colony was selected and cultured in an overnight broth 1YT/Amp₁₀₀ $\mu\text{g/ml}$ /Chloramphenicol₃₄ $\mu\text{g/ml}$ at 37°C. For expression, the overnight starter culture
15 was subcultured by dilution to an A600 = 0.1 in 1YT/Amp₁₀₀ $\mu\text{g/ml}$ /Chloramphenicol₃₄ $\mu\text{g/ml}$ at 37°C in 2L shake flasks at 120rpm. The culture was grown until the A600 reached 0.8-1.0 and then induced with 1mM IPTG, supplemented with Amp100 $\mu\text{g/ml}$ and expression allowed to proceed at 37°C for 4-5 hours.

20 The culture was harvested and centrifuged 5000g in a prechilled rotor at 4°C. The wet weight of the harvested culture was measured and the cell pellet frozen at -80°C. Approximately 3 - 4 grams was produced (wet weight) per litre of cell culture.

25 Lysis and Purification protocol

Extraction of the HepC RdRp (NS5B) was achieved by lysing the cells followed by conventional protein chemistry techniques.

To the frozen cell pellet 5ml of Buffer C (made fresh) at 4°C was added per gram of cell pellet. The mixture was stirred at 4°C using a magnetic bead until the
30 culture was completely resuspended. The culture was then sonicated with 11 bursts each of 10 seconds with 1minute pause between each burst while continually stirring with a magnetic bead throughout the sonication process. The sonicated cells were centrifuged at 75000g at 4°C for 20 minutes and the supernatant (lysate) recovered.

35 A 30% saturation of AmSO₄ was added to the lysate and then centrifuged at 10000g for 15 minutes. This acted to eliminate some bacterial proteins. The pellet

was discarded and to the supernatant a 50% saturation of AmSO_4 was added and centrifuged and again at 10000g for 15 minutes. This acted to precipitate the NS5B from a large proportion of *E.coli* proteins. The supernatant was discarded and the pellet resuspended in half the original volume with Buffer C. This was dialysed in
 5 Buffer C at 4°C overnight.

An aliquot from each step was analysed on SDS PAGE to confirm partial purification of ~90kDa HepC RdRp band.

The dialysed extract was loaded onto a cation exchange column with Hyper D "S" resin pre-equilibrated with Buffer C. The column was then washed with
 10 Buffer C until a stable baseline was achieved. Elution was performed with a step gradient of Buffer C with 1M NaCl. It was found that NS5B eluted at a 50% NaCl ratio corresponding to a 600mM NaCl concentration.

The eluted fractions were analysed on a 10% SDS PAGE to confirm purification. NS5B was purified by this process to over 90% homogeneity with
 15 minor smaller molecular weight contaminating proteins

The purified NS5B was concentrated by 50% saturation with AmSO_4 and resuspension in a volume of Buffer C (with Tris pH 7.4) sufficient to redissolve the pellet. This was then dialysed in the same buffer to eliminate the AmSO_4 .

This purity of the NS5B was such that further purification by size exclusion
 20 chromatography on a preparative Superose 12 column in Buffer C (Tris) was not necessitated, although optional.

	Buffers (Sonication, Lysis, Elution, Dialysis)	Buffer C
	50mM ***Na-PO ₄ pH6.8 Na ₂ HPO ₄	2.32ml
25	{or substitute for Tris pH 6.8	
	NaH ₂ PO ₄	2.69ml }
	100mM NaCl	0.5844g
	10% Glycerol	10ml
	10mM b-Mercaptoethanol	70µl
30	0.02% NaN ₃	80µl
	0.25M Sucrose	8.56g
	0.1% Detergent (β-Octyl Glucopyranoside)	0.1g
	1mM Pefa-Bloc	0.1g
	Complete TM tablets (No EDTA)	2 Tablets
35	H ₂ O	to 100ml

SDS-Polyacrylamide gel electrophoresis (12.5% acrylamide) and coomassie blue staining of the proteins of the purified protein showed a single band at approximately 70kD.

The HepC RdRp (NS5B) was assayed by numerous protocols. The simplest method relies on the Novagen Large Scale Transcription Kit (TB069). Modified forms of this protocol have been used successfully. This method is briefly described as follows.

A double stranded DNA template digested upstream of a T7/T3/SP6 promotor is used in the presence of a T7 DNA dependent RNA polymerase to make the RNA template. HepC RdRp (NS5B) in the same cocktail then amplifies the RNA produced by the T7 polymerase.

	DNA template (0.5µg/ml)	1 µl (0.5ng)
	ATP(20mM)	10 µl
15	CTP(20mM)	10 µl
	GTP(20mM)	10 µl
	UTP (20mM)	10 µl
	5X Transcription buffer (400mM HEPES pH7.5, 60mM MgCl ₂ , 50mM NaCl)	20 µl
20	1M DTT (1M)	1 µl
	T7 polymerase (100U/ml)	1 µl
	HepC RdRp (NS5B)	x µl
25	Nuclease free water	y µl

This method has utilised the control DNA template in the kit as well as plasmid DNA cut upstream of the T7 promotor successfully. The quantity of DNA used has been as low as 0.1ng successfully. The quantity of T7 polymerase used has been as low as 0.1µl.

Interestingly, the HepC RdRp (NS5B) in these experiments has been demonstrated to possess the capacity to prime off dsDNA in the absence of oligonucleotide primers and amplify RNA.

Example 14**Cloning of Hepatitis C RNA dependent RNA polymerase coding sequence into the eukaryotic expression vector pCDNA3.1**

Hepatitis C RNA dependent RNA polymerase coding sequence Figure 10 was
5 cloned into the vector pCDNA3.1 (Figure 9) for expression *in situ* in the coupled
transcription/translation system and concomitant replication/mutation of target
RNA. Sequence of oligonucleotides used as primers in PCR amplification of
Hepatitis C RNA dependent RNA polymerase for cloning into the EcoRI and NotI
restriction sites in the eukaryotic expression vector pCDNA3.1:

10 5' GTGGTGGGAATTCGCCGCCACCTCTATGTCGTACTCTTGGACC
5' GCACGGGCTTGGGCGATAATCCGCCGGCGAGCTCAGATC

Hepatitis C RNA dependent RNA polymerase was cloned into the pCDNA3.1
vector (named pCDNAHEPC) with a strategy similar to that described in example 2
but using the above oligonucleotides in the PCR amplification of the Hepatitis C
15 RNA dependent RNA polymerase from the vector shown in Figure 17. The methods
used to demonstrate that the Hepatitis C RNA dependent RNA polymerase were
being synthesised *in situ* were exactly as described in example 2. The results from
the coupled reaction with the Hepatitis C RNA dependent RNA polymerase
template in pCDNAHEPC are shown in Figure 18. The results shown in this figure
20 demonstrate that Hepatitis C RNA dependent RNA polymerase produces larger
amounts of transcript (scan b) than T7 polymerase alone. Here the band has a
greater intensity and is broader than the band without Hepatitis C RNA dependent
RNA polymerase indicating the effect on the RNA.

It will be appreciated by persons skilled in the art that numerous variations
25 and/or modifications may be made to the invention as shown in the specific
embodiments without departing from the spirit or scope of the invention as broadly
described. The present embodiments are, therefore, to be considered in all respects
as illustrative and not restrictive.

REFERENCES

- Baranov et al. (1989). *Gene* 84:463-466.
- Baranov et al. (1993). *Methods in Enzymology* 217:123-142.
- 5 Barbas et al. (1994). *Ann Rev Imm* 57, 191
- Barrera et al. (1993). *J. Mol. Biol.* 232, 512-521.
- Brown and Gold (1995a). *Biochemistry* 34, 14775-14782.
- Brown and Gold (1995b). *Biochemistry* 34, 14765-14774.
- Brown and Gold (1996). *Proc. Natl. Acad. Sci. (USA)* 93, 11558-11562.
- 10 Coia et al. (1996). *J. Immunol. Meth.* 192, 13-23.
- Deiman et al (1997). *J.Virol.* 71, 5990.
- Duenas and Borrebaeck (1994). *Bio/Technology* 12, 999-1002.
- Ghee et al. (1996). *J. Mol. Biol.* 261, 222-230.
- Gram et al. (1992). *PNAS* 89, 3586.
- 15 Hanes and Pluckthun (1997). *Proc. Natl. Acad. Sci. (USA)* 94, 4937-4942.
- He and Taussig (1997). *Nucleic Acids Research* 25, 5132-5134.
- Irving et al (1996). *Immunotechnology* 2, 127-143.
- Keiler et al. (1996). *Science* 271, 990-993.
- Kigawa et al. (1991). *J. Biochem.* 110, 166-168.
- 20 Kolosov et al. (1992). *Biotechnology and Applied Biochemistry* 16, 125-133.
- Kramer et al. (1978). *Proc. Natl. Acad. Sci. (USA)* 75, 5334-5338.
- Krebber et al. (1995). *FEBS Lett.* 377, 227-331.
- Kudlicki et al. (1992). *Analytical Biochemistry* 206, 389-393.
- Lizardi et al. (1988). *Bio/Technology* 6, 1197-1202.
- 25 Mattheakis et al. (1994). *Proc. Natl. Acad. Sci. (USA)* 91, 9022-9026.
- Melton et al. (1984a). *Nucleic Acid Res.* 12: 7035-56.
- Melton et al. (1984b). *Nucleic Acid Res.* 12: 7057-7070.
- Morozov et al. (1993). *PNAS* 90, 9325-9329.
- Munishkin et al. (1991). *J. Mol. Biol.* 221, 463-472.
- 30 Nishihara et al. (1983). *J.Biochem. (Tokyo)* 93, 669-674.
- Ojala PM and Bamford DH (1995) *Virology*, 207, 400.
- Rattat et al. (1990). *Tibtech* 8, 275-276.
- Rohde et al. (1995). *J Mol Biol* 249, 754-762.
- Ryabova et al. (1989). *Nucleic Acids Research* 17, 4412.
- 35 Ryabova et al. (1989). *Nucleic Acids Research* 17, 4412.
- Ryabova et al. (1994). *Journal of Biological Chemistry* 269, 1501-1506.

- Ryabova et al. (1997). *Nature Biotechnology*, 15, 79-84.
- Sambrook et al. (1989). In: Nolan, C. (Ed.), *Molecular Cloning: A Laboratory Manual*, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Spirin (1990a) US 5556769; 5643768;
- 5 Spirin (1990b). pp. 56-70 in *THE RIBOSOME: STRUCTURE, FUNCTION and EVOLUTION* (eds. Hill, W.E., et al.), Amer. Soc. Microbiol., Washington, D.C.
- Spirin et al. (1988). *Science* 242, 1162-1164.
- Spirin, A.S. (1991). pp 31-43 in *FRONTIERS IN BIOPROCESSING II* (eds. Todd, P. et al.), Amer. Chem. Soc., Washington, D.C.
- 10 Stemmer (1994). *Nature* 370, 389-391.
- Stemmer et al. (1995). *Science* 270, 1510,
- Sumper and Luce (1975). *Proc.Natl. Acad. Sci. (USA)* 72, 162-166.
- Winter et al. (1994). *Ann Rev Biochem* 12, 433,
- Winter et al. (1994). *Ann. Rev. Biochem.* 12, 433.
- 15 Yang et al (1995). *J Mol Biol* 254, 392
- Zamora et al. (1995). *Biochemistry*, 34, 1261-1266.
- Zubay (1973). *Ann. Rev. Genetics* 7, 267-287
- Zucker (1991) *Nucleic Acids Res* 25; 2707-14

Claims:

1. A method for the mutation, synthesis and selection of a protein which binds to a target molecule. the method comprising:
 - 5 (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, wherein the RNA-directed RNA polymerase replicates the mRNA molecule but introduces mutations thereby generating a population of mutant mRNA molecules;
 - 10 (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which result in the synthesis of a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant protein/mRNA complexes;
 - 15 (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule and recovering the mutant protein/mRNA complex(es) bound thereto; and
 - (d) optionally releasing the mRNA molecules from the complex(es).
- 20 2. A method for the mutation, synthesis and selection of a protein which binds to a target molecule. the method comprising:
 - (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA
 - 25 molecule but introduces mutations thereby generating a population of mutant mRNA molecules;
 - (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which result in the synthesis of a population of mutant proteins such that after translation, mutant proteins are linked to their encoding
 - 30 mRNA molecules thereby forming a population of mutant protein/mRNA complexes;
 - (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule;

- (d) repeating steps (a) to (c) one or more times, wherein the replicable mRNA molecule used in step (a) is the mRNA obtained from complex(es) selected in step (c);
- (e) recovering mutant protein complexes bound to the target molecule(s);
- 5 and
- (f) optionally releasing or recovering the mRNA molecules from the complex(es).
3. A method as claimed in claim 2 in which step (d) is repeated more than
- 10 once.
4. A method as claimed in any one of claims 1 to 3 in which the mutant proteins are linked to their encoding mRNA molecules via ribosome complexes.
- 15 5. A method as claimed in any one of claims 1 to 4 in which steps (a) to (d) are carried out simultaneously in either a single or multiple chambered vessel, wherein the multiple chambered vessel allows the transfer of fluids between chambers.
6. A method as claimed in any one of claims 1 to 5 in which the RNA-directed
- 20 RNA polymerase
- (i) introduces mutations into the replicated RNA molecule at a frequency of at least one point mutation in 10^4 bases; or
- (ii) introduces at least one insertion or deletion at a frequency of 10^{-4} .
- 25 7. A method as claimed in any one of claims 1 to 5 in which the RNA-directed RNA polymerase
- (i) introduces mutations into the replicated RNA molecule at a frequency of at least one point mutation in 10^3 bases; or
- (ii) introduces at least one insertion or deletion at a frequency of 10^{-3} .
- 30 8. A method as claimed in any one of claims 1 to 7 in which the RNA-directed RNA polymerase is selected from the group consisting of Q β replicase, Hepatitis C RNA-directed RNA polymerase, Vesicular Stomatitis Virus RNA-directed RNA polymerase, Turnip yellow mosaic virus replicase and RNA bacteriophage phi 6
- 35 RNA-dependent RNA.

9. A method as claimed in any one of claims 1 to 8 in which the RNA-directed RNA polymerase is Q β replicase.
10. A method as claimed in any one of claims 1 to 9 in which the translation system is a cell-free translation system.
11. A method as claimed in claim 10 in which the cell-free translation system comprises an S-30 extract from *Escherichia coli*.
12. A method as claimed in claim 10 in which the cell-free translation system comprises a reticulocyte lysate.
13. A method as claimed in any one of claims 1 to 12 in which the translation system comprises oxidised and/or reduced glutathione at a total concentration of between 0.1mM and 10mM.
14. A method as claimed in claim 13 in which the glutathione concentration is between 2mM and 7mM.
15. A method as claimed in claim 13 in which the translation system comprises oxidised glutathione at a concentration of about 2mM and reduced glutathione at a concentration of between 0.5 mM and 5mM.
16. A method as claimed in any one of claims 1 to 15 in which the replicable mRNA molecule is derived from a template selected from the group consisting of RQ135 RNA, MDV-1 RNA, microvariant RNA, nanovariant RNAs, CT-RNA and RQ120 RNA.
17. A method as claimed in any one of claims 1 to 16 in which the replicable mRNA molecule is derived from a vector which comprises a template selected from MDV-1 RNA and RQ135 RNA.
18. A method as claimed in any one of claims 1 to 17 which further comprises the step of transcribing a DNA template to produce the replicable mRNA.

19. A method as claimed in claim 18 in which the DNA template is a linear DNA molecule.
20. A method as claimed in claim 18 or claim 19 in which the DNA template
5 comprises:
- (i) an untranslated region including a control element which promotes transcription of the DNA into mRNA and a ribosome binding site;
 - (ii) an open reading frame encoding the protein which binds to the target molecule; and
 - 10 (iii) a stemloop structure situated upstream of the open reading frame.
21. A method as claimed in claim 20 in which the stemloop structure is a replicase binding sequence.
- 15 22. A method as claimed in claim 21 in which the replicase binding sequence is between 15 to 50 nucleotides in length.
23. A method as claimed in claim 21 in which the replicase binding sequence is between 20 and 40 nucleotides in length.
- 20 24. A method as claimed in any one of claims 21 to 23 in which the replicase binding sequence is recognised by Q β replicase.
- 25 25. A method as claimed in any one of claims 21 to 24 in which the replicase binding sequence comprises the sequence:
GGGACACGAAAGCCCCAGGAACCUUUCG.
26. A method as claimed in any one of claims 20 to 24 in which a second stemloop structure is included downstream of the open reading frame.
- 30 27. A method as claimed in any one of claims 20 to 26 in which the ribosome binding site is derived from the MS2 virus.
28. A method as claimed in any one of claims 20 to 27 in which a sequence
35 encoding an polypeptide is fused 3' and in frame with the open reading frame.

29. A method as claimed in claim 28 in which the polypeptide is an immunoglobulin constant region.
30. A method as claimed in claim 29 in which the immunoglobulin constant domain is a constant light domain of the mouse antibody 1C3.
31. A method as claimed in any one of claims 1 to 30 in which the target molecule is selected from a DNA molecule, a protein, a receptor, a cell surface molecule, a metabolite, an antibody, a hormone, a bacterium or a virus.
32. A method as claimed in any one of claims 1 to 31 in which the target molecule is bound to a matrix.
33. A method as claimed in claim 32 in which the matrix comprises magnetic beads.
34. A DNA construct comprising:
(i) an untranslated region including a control element which promotes transcription of the DNA into mRNA and a ribosome binding site;
(ii) a cloning site located downstream of the untranslated region; and
(iii) a replicase binding sequence located upstream of the cloning site.
35. A DNA construct as claimed in claim 34 in which the replicase binding sequence is between 15 to 50 nucleotides in length.
36. A DNA construct as claimed in claim 35 in which the replicase binding sequence is between 20 and 40 nucleotides in length.
37. A DNA construct as claimed in any one of claims 34 to 36 in which the replicase binding sequence is recognised by Q β replicase.
38. A DNA construct as claimed in claim 37 in which the replicase binding sequence comprises the sequence: GGGACACGAAAGCCCCAGGAACCUUUCG.
39. A DNA construct as claimed in any one of claims 34 to 38 in which a second replicase binding sequence is included downstream of the cloning site.

40. A DNA construct as claimed in any one of claims 34 to 39 in which the ribosome binding site is derived from the MS2 virus.

5 41. A DNA construct as claimed in any one of claims 34 to 40 in which a sequence encoding a polypeptide located 3' to the cloning site.

42. A DNA construct as claimed in claim 41 in which the polypeptide is an immunoglobulin constant region.

10

43. A DNA construct as claimed in claim 42 in which the immunoglobulin constant domain is a constant light domain of the mouse antibody 1C3.

15 44. A kit for generating a replicable mRNA transcript which comprises a DNA construct as claimed in any one of claims 34 to 43.

45. A kit as claimed in claim 44 which further comprises at least one component selected from the group consisting of:

- 20 (i) an RNA-directed RNA polymerase, preferably Q β replicase, or a DNA or RNA template coding for an RNA-directed RNA polymerase;
- (ii) a cell free translation system;
- (iii) a DNA directed RNA polymerase, preferably a bacteriophage polymerase;
- 25 (iv) ribonucleoside triphosphates; and
- (v) one or more restriction enzymes.

1/22

Affinity Maturation: phage display and ribosome display




Figure 1

2/22





Figure 2

3/22

Figure 3: Continuous *In Vitro* Evolution

4/22

Affinity Maturation: Continuous In Vitro Evolution device




Figure 4

5/22

Figure 5

Figure 5(a) Sequence of Constant Light Region of mouse monoclonal 1C3

GCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGA
GGTGCCTCAGTCGTGTGCTTCTTGAACAATTCTACCCCAAAGACATCAATGTCAAGTGG
AAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAG
CAAAGACAGCACCTACAGCATGAGCAGCACCCCTCACGTTGACCAAGGACGAGTATGAAC
GACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAAGA
GCTTCAACAGGGGAGAGTGT

Figure 5(b) Sequence of Human Constant Heavy Chain

GCAGATCAAGACACAGCCATCCGGGTCTTCGCCATCCCCCATCCTTTGCCAGCATCTTC
CTCACCAAGTCCACCAAGTTGACCTGCCTGGTCACAGACCTGACCACCTATGACAGCGT
GACCATCTCCTGGACCCGCCAGAATGGCGAAGCTGTGAAAACCCACACCAACATCTCCG
AGAGCCACCCCAATGCCACTTTCAGCGCCGTGGGTGAGGCCAGCATCTGCGAGGATGA
CTGGAATTCCGGGGAGAGGTTACGTGCACCGTGACCCACACAGACCTGCCCTCGCCAC
TGAAGCAGACCATCTCCCGGCCCAAGGGC

Figure 5(c) Sequence of the anti-glycophorin (1C3) scFv

ATGGCCGAGGTGAGGCTTCTTGAGTCTGGAGGTGGCCCGGTACAACCTGGAGGATCCC
TGAAACTCTCCTGTGCAGCCTCAGGATTCGATTTTAGTAGATACTGGATGAATTGGGTCC
GGCGGGCTCCAGGGAAGGGGCTAGAGTGGATTGGAGAAATTAATCAACAAAGCAGTAC
GATAAACTATTCGCCACCTCTGAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAGT
ACGCTGTACCTGCAAATGAACAAAGTGAGATCTGAGGACACAGCCCTTTATTATTGTGCA
AGACTTTCTCTTACTGCGGCAGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACCGT
CGCCTCCGGTGGTGGTGGTTCAGGAGGAGGAGGTTCCGGTGGTGGTGGTTCGGACATC
GTCATGTCACAGTCTCCATCCTCCCTGGCTGTGTGCTAGGAGAGAAGGTCACTATGAG
CTGCAGATCCAGTCAGAGTCTGTTCAACAGTAGAACCCGAAAGAACTACTTGACTTGGTA
CCAGCAGAAACCAGGGCAGTCTCCTAAACCGCTGATCTACTGGGCATCCACTAGGGAAT
CTGGGGTCCCTGATCGCTTACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATC
AGCAGTGTGCAGGCTGAAGACCTGGCAGATTATTACTGCAAGCAATCTTATAATCTTCGG
ACGTTCCGGTGGAGGCACCAAGCTGGAAATCAAACGGG

Figure 5(d) Sequence of the anti-Hepatitis Surface antigen (4C2) scFv

CCATGGCCGATGTGAAGCTTCAGGAGTCAGGGCCTGAGCTGGTGAGGCCCGGGGTCTC
AGTGAAGATTACCTGCAAGGGTCCGGCTACACATTCAGTATTATGCTATGCATTGGGT
GAAGCAGAGTCATGCCAAGAGTCTAGAGTGGATTGGACTTATTAGTAATTCCTTGGTAA

6/22

TACAAACTACAACCAGAAGTTTGAGGCCAAGGCCACAATGACTGTAGACAAATCCTCCAA
CACAGGCTATTTGGAAC TTGGCAGATTGACATCTGAGGATTCTGCCATCTATTACTGTGC
AAGAGTGATCGACTGGTCCTTCGATGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCT
CAGGTGGAGGCGGTT CAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATTGTGC
TGACCCAATCTCCAGCAATCATGTT CGCATCTCCAGGGGAGAAGGTCACCATGACCTGCA
GTGCCAACTCACGTGTCAGGTACGTGCACTGGTACCAACAGAAGTCAGGCACCTCCCCC
AAAAGATGGATTTATGACACATCCAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGC
AGTGGGTCTGGGACCTCTCACTCTCTACAATCAGCAGCTTGGAGGCTGAAGATGCTGC
CACTTATTACTGCCAGCACTGGAGTAGTAACCCCTCCACGTTCCGGTGCTGGGACCAAGCT
GGAAATAAAACGGGCGGCCGCAGATTATAAAGATGATGATAAAGCCGCGGCCCATC
ACCACCATCACCATTAAGAATTCAGCCCGCCTAATG

Figure 5 (cont'd)

SUBSTITUTE SHEET (Rule 26) (RO/AU)

7/22

Figure 6

GGGGACCCCTTTAGGGGGTCACCTCACACAGCAGTACTTCACTGAGTATAAGAGGACA
TATGCCTAAATTACCGCGTGGTCTGCGTTTCGGAGCCGATAATGAAATTCCTAATGATTTT
CAGGAGCTCTGGTTTCCAGACCTCTTTATCGAATCTTCCGACACGCATCCGTGGTACACA
CTGAAGGGTCGTGTGTGAACGCCACCTTGATGATCGTCTACCTAATGTAGGCGGTGCG
CCAGGTAAGGCGCACTCCACATCGCGTCACCGTTCCGATTGCCTCTTCAGGCCTTCGTC
CGGTAACAACCGTTCAGTATGATCCCGCAGCACTATCGTTCTTATTGAACGCTCGTGTTG
ACTGGGATTTCCGTAATGGCGATAGTGCGAACCTTGTCATTAATGACTTTCTGTTTCGCA
CCTTTGCACCTAAGGAGTTTGATTTTTCGAACTCCTTAGTTCCTCGTTATACTCAGGCCTT
CTCCGCGTTTAATGCCAAGTATGGCACTATGATCGGCGAAGGGCTCGAGACTATAAAATA
TCTCGGGCTTTTACTGCGCAGACTGCGTGAGGGTTACCGCGCTGTAAAGCGTGGCGATT
TACGTGCTCTTCGTAGGGTTATCCAGTCCTACCATAATGGTAAGTGGAAACCGGCTACTG
CTGGTAATCTCTGGCTTGAATTCGTTATGGCCTTATGCCTCTCTTTTATGACATCAGAGA
TGTCATGTTAGACTGGCAGAACCGTCATGATAAGATTCAACGCCTCCTTCGGTTTTCTGTT
GGTCACGGCGAGGATTACGTTGTGCAATTCGACAATCTGTACCCTGCCGTTGCTTACTTT
AACTGAAAGGGGAGATTACACTCGAACGCCGTCATCGTCATGGCATATCTTACGCTAAC
CGCGAAGGATATGCTGTTTTCGACAACGGTTCCTTCGGCCTGTGTCCGATTGGAAGGA
GCTTGCCACTGCATTCAATCCGCATGAAGTTGCTTGGGAGTTAACTCCCTACAGCTT
CGTTGTTGATTGGTTCTTGAATGTTGGTGACATACTTGCTCAACAAGGTCAGCTATATCAT
AATATCGATATTGTAGACGGCTTTGACAGACGTGACATCCGGCTCAAATCTTTCACCATAA
AAGGTGAACGAAATGGGCGGCCTGTTAACGTTTCTGCTAGCCTGTCTGCTGTCGATTTAT
TTTACAGCCGACTCCATACGAGCAATCTTCCGTTGCTACACTAGATCTTGATACTACCTT
TAGTTCGTTTAAACACGTTCTTGATAGTATCTTTTTATTAACCCAACGCGTAAAGCGTTGA
AACTTTGGGTCAATTTGATCATGGCAAATTAGAGACTGTTACTTTAGGTAACATCGGGAA
AGATGGAACAACTCTGGTCCTCAATCCGCGTGGGGTAAATCCCACTAACGGCGTTG
CCTCGCTTTCACAAGCGGGTGCAGTTCCTGCGCTGGAGAAGCGTGTTACCGTTTCGGTA
TCTCAGCCTTCTCGCAATCGTAAGAACTACAAGGTCCAGGTTAAGATCCAGAACCCGACC
GCTTGCACTGCAAACGGTTCCTGTGACCCATCCGTTACTCGCCAGGCATATGCTGACGTG
ACCTTTTCGTTACGCGAGTATAGTACCGATGAGGAACGAGCTTTTGTTTCGTACAGAGCTT
GCTGCTCTGCTCGCTAGTCTCTGCTGATCGATGCTATTGATCAGCTGAACCCAGCGTAT
TGAACACTGCTCATTGCCGGTGGTGGCTCAGGGTCAAAACCCGATCCGGTTATTCCGGA
TCCACCGATTGATCCGCCGCCAGGGACAGGTAAGTATACCTGTCCCTTCGCAATTTGGTC
CCTAGAGGAGGTTTACGAGCCTCCTACTAAGAACCGACCGTGCCCTATCTATAATGCTGT
TGAACCTCAGCCTCGCGAATTTGATGTTGCCCTCAAAGATCTTTTGGGCAATACAAAGTG
GCGTGATTGGGATTCTCGGCTTAGTTATACCACGTTCCGCGGTTGCCGTGGCAATGGTT
ATATTGACCTTGATGCGACTTATCTTGCTACTGATCAGGCTATGCGTGATCAGAAGTATGA

8/22

TATTCGCGAGGGCAAGAAACCTGGTGCTTTCGGTAACATTGAGCGATTCAATTTATCTTAA
GTCGATAAATGCTTATTGCTCTCTTAGCGATATTGCGGCCTATCACGCCGATGGCGTGAT
AGTTGGCTTTTGGCGCGATCCATCCAGTGGTGGTGCCATACCGTTTGACTTCACTAAGTT
TGATAAGACTAAATGTCCTATTCAAGCCGTGATAGTCGTTCTCGTGCTTAGTAACCTAAGG
ATGAAATGCATGTCTAAGACAGCATCTTCGCGTAACCTCTCTCAGCGCACAAATTGCGCCGA
GCCGCGAACACAAGAATTGAGGTTGAAGGTAACCTCGCACTTTCCATTGCCAACGATTTA
CTGTTGGCCTATGGTCAGTCGCCATTTAACTCTGAGGCTGAGTGTATTTCAATTCAGCCCG
AGATTCGACGGGACCCCGGATGACTTTAGGATAAATTATCTTAAAGCCGAGATCATGTCG
AAGTATGACGACTTCAGCCTAGGTATTGATACCGAAGCTGTTGCCTGGGAGAAGTTCCTG
GCAGCAGAGGCTGAATGTGCTTTAACGAACGCTCGTCTCTATAGGCCTGACTACAGTGA
GGATTTCAATTTCTCACTGGGCGAGTCATGTATACACATGGCTCGTAGAAAAATAGCCAA
GCTAATAGGAGATGTTCCGTCCGTTGAGGGTATGTTGCGTCACTGCCGATTTTCTGGCG
GTGCTACAACAACGAATAACCGTTCGTACGGTCATCCGTCCTTCAAGTTTGCGCTTCCGC
AAGCGTGTACGCCTCGGGCTTTGAAGTATGTTTTAGCTCTCAGAGCTTCTACACATTTG
ATATCAGAATTTCTGATATTAGCCCTTTAATAAAGCAGTACTGTACCTAAGAACAGTAA
GACAGATCGTTGTATTGCTATCGAACCTGGTTGGAATATGTTTTTCCAAGTGGGTATCGG
TGGCATTCTACGCGATCGGTTGCGTTGCTGGGGTATCGATCTGAATGATCAGACGATAAA
TCAGCGCCGCGCTCACGAAGGCTCCGTTACTAATAACTAGCAACGGTTGATCTCTCAGC
GGCAAGCGATTCTATATCTTGGCCTCTGTGAGCTCTTATTGCCCCAGGCTGGTTTGA
GGTCTTATGGACCTCAGATCACCTAAGGGGGCGATTGCCTGACGGTAGTGTTGTACCTA
CGAGAAGATTTCTTCTATGGGTAACGGTTACACATTCGAGCTCGAGTCGCTTATTTTGTCT
TCTCTCGCTCGTTCCGTTTGTGAGATACTGGACTTAGACTCGTCTGAGGTCACTGTTTAC
GGAGACGATATTATTTTACCGTCCTGTGCAGTCCCTGCCCTCCGGGAAGTTTTTAAGTAT
GTTGGTTTTACGACCAATACTAAAAAGACTTTTTCCGAGGGGCCGTTTACAGAGAGTCGTGC
GGCAAGCACTACTATTCTGGCGTAGATGTTACTCCCTTTTACATACGTCACCGTATAGTGA
GTCCTGCCGATTTAATACTGGTTTTGAATAACCTATATCGGTGGGCCACAATTGACGGCG
TATGGGATCCTAGGGGCCATTCTGTGTACCTCAAGTATCGTAAGTTGCTGCCTAAACAGC
TGCAACGTAATACTATACCTGATGGTTACGGTGATGGTGCCCTCGTCGGATCGGTCCTAA
TCAATCCTTTTCGCGAAAAACCGCGGGTGGATCCGGTACGTACCGGTGATTACGGACCAT
ACAAGGGACCGAGAGCGCGCTGAGTTGGGGTCGTATCTCTACGACCTCTTCTCGCGTTG
TCTCTCGGAAAGTAACGATGGGTTGCCTCTTAGGGGTCCATCGGGTTGCGATTCTGCGG
ATCTATTTGCCATCGATCAGCTTATCTGTAGGAGTAATCCTACGAAGATAAGCAGGTCTAC
CGGCAAATTCGATATACAGTATATCGCGTGCACTAGCCGTGTTCTGGCACCCCTACGGGG
TCTTCCAGGGCACGAAGGTTGCGTCTCTACACGAGGCGTAACCTGGGAGGGCGCCAATA
TGGCGCCTAATTGTGAATAAATTATCACAATTACTCTTACGAGTGAGAGGGGGATCTGCT
TTGCCCTCTCTCTCCCGGGGGATCCACTAGTTCTAGGTACTCGGGCAGCGTTGGGTCC
TGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGG
GTTGCCCTTACTGGTTAGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGC

Figure 6 (cont'd)

9/22

TGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCG
TAAAGTCTGAAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGC
AGGATGCTGCTGGCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCGCTGGCATTG
ACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACA
ACGTTCCAGTAACCGGGCATGTTTCATCATCAGTAACCCGATCGTGAGCATCCTCTCTCG
TTTCATCGGTATCATTACCCCCATGAACAGAAATTCCCCCTTACACGGAGGCATCAAGTG
ACCAAACAGGAAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAAAG
CTTCTGGAGAACTCAACGAGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCT
TCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTG
AAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCC
GGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCA
GCCATGACCCAGTCACGTAGCGATAGCGGAGTGATACTGGCTTAACATGCGGCATCA
GAGCAGATTGTAAGTGCAGGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAG
GAGAAAAACCGCATCAGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGG
TCGTTCCGGCTGCGGGCAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACA
GAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAA
CCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATC
ACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAG
GCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGG
ATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGCGCTTTCTCATAGCTCACGCTGTAG
GTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACATCGTCTTGAGTCCAACCCGGTAAGAC
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTA
GGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTG
ATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTAC
GCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA
GTGGAACGAAAACACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCAC
CTAGATCCTTTTAAATTAATAAAGTAAATCAATCTAAAGTATATATGAGTAACTT
GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTT
GTTTCATCCATAGTTGCCTGACTCCCCGTGCTGTAGATAACTACGATACGGGAGGGCTTAC
CATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACC GGCTCCAGATTTA
TCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA
TAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTG
GTATGGCTTCATTACAGCTCCGGTCCCAACGATCAAGGCGAGTTACATGATCCCCATGT
TGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCC
GCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCG

Figure 6 (cont'd)

10/22

TAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGATGC
GGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGA
ACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTAC
CGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGACCCCAACTGATCTTCAGCATCTT
TTACTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGG
GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAG
CATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAA
CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATT
ATTATCATGACATTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAAT
TGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGC
TGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCC
GCTACAGGGCGCGTCCCATTCGCCATTCAGGCTACGCAACTGTTGGGAAGGGCGATCG
GTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAGGGGGGATGTGCTGCAAGGCGAT
TAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGTTGTAAACGACGGCCAGTGAA
TTGTAATACGACTCACTATA

Figure 6 (cont'd)

SUBSTITUTE SHEET (Rule 26) (RO/AU)

11/22

Figure 7a





Figure 7b



12/22






Figure 8

13/22

Figure 9



14/22

Figure 10

HCV NS5B (polymerase) sequence [1716 bases]

5'TCTATGTCGTA CTCTTGGACCGGCGCCCTGATAACACCGTG TAGTGCT
GAGGAGGAGAACTGCCCATCAGCCCACTCAGCAACTCCTTGCTGAGAC
ATCATAACCTAGTCTATTCAACGTCGTCTAGAAGCGCTTCTCAGCGTCAG
AGGAAGGTTACCTTCGACAGACTGCAGGTGCTCGACGACCATTACAAGA
CTGTATTAAAGGAGGTAAAGGAGCGAGCGTCTAGGGTAAAGGCTCGCAT
GCTCACCATCGAGGAAGCGTGCGCGCTCGTCCCTCCTCACTCTGCCCGG
TCGAAATTTCGGGTATAGTGCGAAGGACGTTTCGCTCCTTGTCTAGCAGGG
CCATTAACCAGATCCGCTCCGTCTGGGAGGACTTGCTAGAAGACACCAC
AACTCCAATTCCAACCACCATCATGGCGAAGAACGAGGTGTTTTGTGTGG
ACCCCGCTAAAGGGGGCCGCAAGCCCGCTCGCCTTATCGTGTACCCTGA
CCTGGGGGTTCTGTCTGCGAGAAACGCGCCCTATATGACGTGATACAG
AAGTTGGCAATTGAGACGATTGGTTCTGCTTACGGATTCCAATACTCGCC
TCAACAGCGGGTCGAACGTCTGCTCAAGATGTGGACCTCAAAGAAAACC
CCCTTGGGGTTCTCGTATGACACCCGCTGCTTTGACTCAACTGTCACTGA
ACAGGACATCAGGGTGGAAGAGGAGATATACCAATGCTGCAACCTTGAA
CCGGAGGCCAGGAAAGTGATCTCCTCCCTCACGGAGCGGCTTTACTGCG
GGGGCCCTATGTTCAACAGCAAGGGGGCTCAGTGTGGTGACCGTCGTTG
CCGTGCCAGTGGAGTTTTGCCTACCAGCTTTGGCAATACAATCACTTGTT
ACATCAAAGCCACAGCGGCTGCGAACGGCGCAGGCCTCCGGGACCCGGA
CTTTCTTGTCTGCGGAGATGATCTGGTCGTGGTGGCCGAGAGTGACGGC
GTCGATGAGGATGGGGCAGCCCTGAGAGCCTTCACGGAGGCTATGACCA
GGTATTCTGCTCCACCCGAGATGCTCCACAGCCCACTACGACCTTGA
GCTCATCACATCTTGCTCCTCCAACGTCTCCGTGGCACGGGACGACAAG
GGGAGGAGGTACTATTACCTCACCCGTGATGCCACCACTCCCTAGCCC
GTGCGGCTTGGGAAACAGCTCGTCACACTCCAGTTAACTCCTGGTTAGG
TAACATCATCATGTACGCGCCTACCATCTGGGTGCGCATGGTAATGATGA
CACACTTTTTCTCCATACTCCAATCCCAGGAGATACTTGATCGACCCCTT
GACTTCGAAATGTACGGGGCCACTTACTCGGTACGCCGCTGGATTAC
CAGCAATCATTGAAAGACTCCATGGTCTAAGCGCGTTACGCTCCACAGT
TACTCTCCAGTAGAGCTCAATAGGGTCGCGGGGACACTCAGGAAGCTGG
GGTGCCCCCCCCCTACGAGCTTGGAGACATCGGGCACGAGCAGGGCGCGC
TAAGCTTATCGCCCAGGGAGGGAAGGCCAAAATATGCGGCCTTTATCTC
TTTAATTGGGCGGTACGCACCAAGACCAAACTCACTCCGCTGCCACGCG
CTGGCCAGTTGGATTTATCCATCTGGTTTACGGTTGGCGTCGGCGGGAA
CGACATTTATCACAGCGTGTCGCGTGCCCGAACCCGCTATTAG 3'

15/22


Figure 11

N5266 GCG CGA ATA CGA CTC ACT ATA GAG GGA CAA ACC GCC ATG GCC GAG GTG
 AGG CTT CTT GAG TCT GG
 N5267 CAT CAT CAT CAT CTT TAT AAT CTG CGG CCG CAC ACT CTC CCC TGT TGA
 AGC TCT TGA C
 N5268 CCC CTG TTG AAG CTC TTG ACA ATG GGT GAA GTT GAT GTC TTG TGA GTG
 GCC TCA CAG
 N5269 CTT GTG AGT GGC CTC ACA GGT ATA GCT GTT ATG TCG TTC ATA CTC G
 N5343 ACC ATG ATT ACG CCA AGC TCT AAT ACG ACT CAC TAT AGG GAA AGC TCG
 CTT GTT C
 N5344 AGG GAA AGC TCG CTT GTT CTT TTT GCA GAA GCT CAG AAT AAA CGC TCA
 ACT TTG GCC ACC
 N5353 TTT ATA ATC TGC GGC CGC CGC CTC GTG TAG AGA CGC AAC
 N5354 TTA CTC GCG GCC CAG CCG GCC ATG GCC ATG TCT AAG ACA GCA TCT TCG
 N5659 GC AGC TAA TAC GAC TCA CTA TAG GAA CAG ACC ACC ATG GAC GTG GCC
 CAG CCT GCT GTG G
 N5384 AAA CGC TCA ACT TTG GCC ACC ATG GAT GTG AAG CTT CAG GAG TCT GGG
 CC
 N5385 GCC CTT GGG CCG GGA GAT GGT CTG CTT CAG TGG CGA GGG CAG GTC
 TGT GTG
 N5386 CGA GGG CAG GTC TGT GTG GGT CAC GGT GCA CGT GAA CCT CTC CCC
 GGA G
 N5387 CGT GAA CCT CTC CCC GGA GTT CCA GTC ATC CTC GCA GAT GCT GGC CTC
 ACC
 N5517 GCG CGA ATA CGA CTC ACT ATA GAG GGA CAA ACC GCC ATG GCC GAT GTG
 AAG CTT CAG GAG TCA GG
 N5659 GC AGC TAA TAC GAC TCA CTA TAG GAA CAG ACC ACC ATG GAC GTG GCC
 CAG CCT GCT GTG G
 N5904 TAA TAC GAC TCA CTA TAG GGA AAG GGT TTC TCC GAT CCG GGA ACA TAG
 GAT ACC
 N5909 TGA GGT ATC CTA TGT TCC CGG ATC GGA GAA ACC CAC ACT CTC CCC TGT
 TGA AGC TCT TGA C
 N5910 CCG GGA ACA TAG GAT ACC TCA ACC ACC ATG GCC GAG GTG AGG CTT CTT
 GAG TCT GG

16/22

Figure 12


Q Beta replicase expression



17/22

Figure 13

Translation in rabbit reticulocyte cell-free system:
effect of Q β replicase on 1C3 coupled transcription/translation



1 29 57 85 113 141 169 197


18/22

Figure 14

Sequence Name	Form of Q β Replicase	Mutation Found
A1	Not included	None
A2	Not included	None
A3	Not included	None
A4	Not included	None
A5	Not included	T149C
A6	Not included	None
B1	Purified	A134G
B2	Purified	A279G
B3	Purified	None
B4	Purified	None
B5	Purified	T89C; G98C; A172C; T244C; A251C
B6	Purified	None
C1	pCDNAQ β	T59C; A129G; A160G
C2	pCDNAQ β	None
C3	pCDNAQ β	A30C; G82A;
C4	pCDNAQ β	None
C5	pCDNAQ β	None
C6	pCDNAQ β	A257G

19/22

Figure 15



20/22


Figure 16

Mutation of Replicated RNA by RNA dependent Polymerases: List of Representative Mutations Chosen at Random.

Coding region; Clone#	Replicase	Mutations
G1 (anti GlyA 1C3 scFv)	None	None
G2	Q β purified	G124C, T234C, T329C, G367C, C379T, G385A
G3	Q β purified	T507G, C527-delete, C543T, C557T
G4	Q β purified	G136A, insert-141A, -164G, G216A, G330-delete, G429A, C506T, T634C
G5	Q β purified	C208A, G210C, -211G, C213T, G320A, C403T, C597A
G6	Q β purified	Deletion 120-441, A440G, G605A,
G7	Q β purified	A475T, A580C,
G8	Q β purified	A23C, G23A, G25A, G29A, G109A, G322A, C398T
G9	Q β purified	G151T, C221-delete, C237T, C249T,
HB1 (anti Hepb 4C2 scFv)	None	None
HB2	Q β purified	G239C, G486T, G354C,
HB3	Q β purified	A205C, T304G
HB4	Q β purified	A206C, G274C, T282-delete, T285-delete, G328-delete, G338-C350 substitute irrelevant sequence
HB5	Q β purified	T397G, G398A,
HB6	Q β purified	T561C
GC1(antiGlyA1C3 scFv)	pCDNAHepC	C57T, G221A, C557T
GC2	HepC purified	Deletion 110-162
GC3	HepC purified	Deletion 77-165
GC4	HepC purified	C353A, C366T,

Figure 17


pGE-lysN vector map, source of NS5B
(Hepatitis C RNA dependent RNA polymerase) sequence)



22/22

Figure 18

Effect of hepatitis C RdRP expressed in situ on 1C3 scFv RNA template
in coupled reaction: RT-PCR



SEQUENCE LISTING

5
 <110> CRC for Diagnostic Technologies
 <120> Continuous one step in-vitro evolution

10 <130> 91662
 <140>
 <141>

15 <160> 26
 <170> PatentIn Ver. 2.1

SEQ ID NO: 1
 20 <211> 318
 <212> DNA
 <213> Murine Immunoglobulin Sequence

<220>
 25 <223> Description of Sequence: Mouse antibody
 IC3 constant region

<400> 1
 30 gctgatgctg caccaactgt atccatcttc ccaccatcca gtgagcagtt aacatctgga 60
 ggtgcctcag tcgtgtgctt cttgaacaac ttctacccca aagacatcaa tgtcaagtgg 120
 aagattgatg gcagtgaacg acaaaatggc gtcctgaaca gttggactga tcaggacagc 180
 aaagacagca cctacagcat gagcagcacc ctcacgttga ccaaggacga gtatgaacga 240
 cataacagct atacctgtga ggccactcac aagacatcaa cttcaccat tgtcaagagc 300
 ttcaacaggg gagagtgt 318

35
 SEQ ID NO: 2
 <211> 2004
 <212> DNA
 <213> Homo sapiens

40
 <220>
 <223> Description of Sequence: Human antibody
 IC3 constant region

45 <400> 2
 gcagatcaag acacagccat ccgggtcttc gccatcccc catcctttgc cagcatcttc 120
 ctaccaagt ccaccaagt gacctgctg gtcacagacc tgaccaccta tgacagcgtg 180
 accatctcct ggaccgcca gaatggcgaa gctgtgaaaa cccacaccaa catctccgag 240
 agccaccca atgccacttt cagcgccgtg ggtgaggcca gcacttgcca ggatgactgg 300
 50 aattccgggg agaggttcac gtgcaccgtg acccacacag acctgccctc gccactgaag 360
 cagaccatct cccggcccaa gggc

SEQ ID NO: 3
 <211> 748
 55 <212> DNA
 <213> Homo sapiens

<220>
 <223> Description of Sequence: Antiglycophorin
 60 IC3 SCFV

2/9

```

<400> 3
atggccgagg tgaggcttct tgagtctgga ggtggcccg tacaacctgg aggatccctg 60
aaactctcct gtgcagcctc aggattcgat tttagtagat actggatgaa ttgggtccgg 120
5 cgggctccag ggaaggggct agagtggatt ggagaaatta atcaacaaag cagtacgata 180
aactattcgc cacctctgaa ggataaattc atcatctcca gagacaacgc caaaagtacg 240
ctgtacctgc aaatgaacaa agtgagatct gaggacacag ccctttatta ttgtgcaaga 300
ctttctctta ctgaggcagg gtttgcttac tggggccaag ggactctggt caccgtcgcc 360
tccggtgggt gtggttcagg aggaggaggt tccggtgggt gtggttcgga catcgctatg 420
10 tcacagtcct catcccccct ggctgtgtca gtaggagaga aggtcactat gagctgcaga 480
tccagtcaga gtctgtctaa cagtagaacc cgaaagaact acttgacttg gtaccagcag 540
aaaccagggc agtctcttaa accgctgac tactgggcat ccactagga atctgggggc 600
cctgatcgct tcacaggcag tggatctggg acagatttca ctctaccat cagcagtgtg 660
caggctgaag acctgtcaga ttattactgc aagcaatctt ataatcttcg gacgttcggg 720
15 ggaggcacca agctgtgaaat caaacggg

```

SEQ ID NO: 4

<211> 807

<212> DNA.

20 <213> Homo sapiens

<220>

<223> Description of Sequence: Antihepatitis
surface antigen (4C2) SCFV

25

```

<400> 4
ccatggccga tgtgaagctt caggagtcag ggcctgagct ggtgaggccc ggggtctcag 60
tgaagattac ctgcaagggt tccggctaca cattcactga ttatgctatg cattgggtga 120
agcagagtca tgccaagagt cttagagtga ttggacttat tagtaattcc tttggtaata 180
30 caaactacaa ccagaagttt gaggccaagg ccacaatgac tgtagacaaa tcttccaaca 240
caggctatctt ggaacttggt agattgacat ctgaggattc tgccatctat tactgtgcaa 300
gagtgatcga ctgggtcttc gatgtctggg gccaaaggac cagggtcacc gtctcctcag 360
gtggaggcgg ttcaaggcga ggtggctctg gcgggtggcg atcggacatt gtgctgacct 420
aatctccagc aatcatgttc gcatctccag gggagaaggt caccatgacc tgcagtgcc 480
35 actcacgtgt cagggtacgt cactgggtacc aacagaagtc aggcacctcc cccaaaagat 540
ggatttatga cacaacaaa ctggcttctg gattccctgc tcgcttcagt ggcagtgggt 600
ctgggacctc tcaactcttc acaatcagca gcttgaggc tgaagatgct gccacttatt 660
actgccagca ctggagttagt aaccctccca cgttcggtgc tgggaccaag ctggaaataa 720
aacgggcggc cgcaatttat aaagatgatg atgataaagc cgcggcccat caccaccatc 780
40 accattaaga attcagcccg cctaagt

```

SEQ ID NO: 5

<211> 7489

<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificial
plasmid pERT7Q beta

50

```

<400> 5
ggggaccccc tttatggggg cacctcacac agcagtactt cactgagtat aagaggacat 60
atgcctaaat taccgtgtg tctgcgtttc ggagccgata atgaaattct taatgatttt 120
caggagctct ggttttcaga cctctttatc gaatcttccg acacgcaccc gtggtacaca 180
55 ctgaagggtc gtgtttgaa cgcccacctt gatgatcgtc tacctaattg aggcggtcgc 240
caggtaaggc gcacttcaca tcgcgtcacc gttccgattg cctcttcagg ccttcgtccg 300
gtaacaaccg ttcaattatga tccgcagca ctatcgttct tattgaacgc tcgtgttgac 360
tgggatttcg gtaattgcga tagtgcaaac cttgtcatta atgactttct gtttcgcacc 420
tttgcacctt aggaattga tttttcgaac tccttagttc ctcgttatac tcaggecttc 480
60 tccgcgttta atgcgaagta tggcactatg atcggcgaag ggctcgagac tataaaatat 540
ctcgggcttt tactgtcgag actgcgtgag ggttaccgag ctgttaagcg tggcgattta 600

```

	cgtgctcttc	gtaggggttat	ccagtcctac	cataatggta	agtggaaacc	ggctactgct	660
	ggtaatctct	ggcttgaatt	tcgttatggc	cttatgcctc	tcttttatga	catcagagat	720
	gtcatgttag	actggcagaa	ccgtcatgat	aagattcaac	gcctccttcg	gttttctggt	780
	ggtcacggcg	aggat-acgt	tgtcgaattc	gacaatctgt	accctgccgt	tgcttacttt	840
5	aaactgaaag	gggagattac	actcgaacgc	cgtcatcgtc	atggcatatc	ttacgctaac	900
	cgcgaaggat	atgctgtttt	cgacaacggg	tcccttcggc	ctgtgtccga	ttggaaggag	960
	cttgccactg	cattcatcaa	tccgcatgaa	gttgcttggg	agttaactcc	ctacagcttc	1020
	gttgttgatt	ggttcttgaa	tgttggtgac	atacttgctc	aacaagggtca	gctatatcat	1080
	aatatcgata	ttgtagacgg	ctttgacaga	cgtgacatcc	ggctcaaate	tttcaccata	1140
10	aaaggtgaac	gaaatgggcg	gcctgttaac	gtttctgcta	gcctgtctgc	tgctgattta	1200
	ttttacagcc	gactccatac	gagcaatctt	ccgttcgcta	cactagatct	tgatactacc	1260
	tttagttcgt	ttaaacacgt	tcttgatagt	atctttttat	taacccaacg	cgtaaagcgt	1320
	tgaacttttg	ggccaatttg	atcatggcaa	aattagagac	tgttacttta	ggtaacatcg	1380
	ggaaagatgg	aaaaacaaact	ctggctctca	atccgcgtgg	ggtaaatccc	actaacggcg	1440
15	ttgcctcgct	ttcacaagcg	gggtgcagttc	ctgcgctgga	gaagcgtggt	accgtttcgg	1500
	tatctcagcc	ttctcgaat	cgtaaagaact	acaagggtcca	ggtaagatc	cagaacccga	1560
	ccgcttgac	tgcaaacggg	tcttgtagacc	catccgttac	tcgccaggga	tatgctgacg	1620
	tgaccttttc	gttcaagcag	tatagtaccg	atgaggaacg	agctttttgt	cgtacagagc	1680
	ttgctgctct	gctcgttagt	cctctgctga	tcgatgctat	tgatcagctg	aacccagcgt	1740
20	attgaacact	gctcattgcc	gggtggtggct	caggggtcaaa	acccgatccg	gttattccgg	1800
	atccaccgat	tgattcgccg	ccagggacag	gtaagtatac	ctgtcccttc	gcaatttggt	1860
	ccctagagga	ggttacagag	cctcctacta	agaaccgacc	gtggcctatc	tataatgctg	1920
	ttgaactcca	gcctcgcgaa	tttgatgttg	ccctcaaaga	tcttttgggc	aatacaaagt	1980
	ggcgtgattg	ggattctcgg	cttagttata	ccacgttccg	cggttgccgt	ggcaatgggt	2040
25	atattgacct	tgatcgact	tatcttgcta	ctgatcaggc	tatgctgat	cagaagtatg	2100
	atattcgca	gggcaagaaa	cctggtgctt	tcggtaacat	tgagcgattc	atttatctta	2160
	agtcgataaa	tgcttattgc	tctcttagcg	atattgcggc	ctatcacgcc	gatggcgtga	2220
	tagttggctt	ttggcgcgat	ccatccagtg	gtggtgccat	accgtttgac	ttcactaagt	2280
	ttgataagac	taaa-gtcc	attcaagccg	tgatagtcgt	tcctcgtgct	tagtaactaa	2340
30	ggatgaaatg	catgcttaag	acagcatctt	cgcgtaaact	tctcagcgca	caattgcgcc	2400
	gagccgcgaa	cacaagaatt	gaggttgaag	gtaacctcgc	actttccatt	gccaacgatt	2460
	tactgttggc	ctatggtcag	tcgccattta	actctgaggc	tgagtgtatt	tcattcagcc	2520
	cgagattcga	cgggaccccc	gatgacttta	ggataaatta	tcttaaagcc	gagatcatgt	2580
	cgaagtatga	cgacttcagc	ctagggtattg	ataccgaagc	tggtgcctgg	gagaagttcc	2640
35	tggcagcaga	ggctgaatgt	gctttaacga	acgctcgtct	ctatagcct	gactacagtc	2700
	aggatttcaa	tttctcactg	ggcagtcac	gtatacacat	ggctcgtaga	aaaatagcca	2760
	agctaatagg	agatgctccg	tccgttgagg	gtatgttgcg	tactgcgga	ttttctggcg	2820
	gtgctacaac	aacgaataac	cgttcgtacg	gtcatccgtc	cttcaagttt	gcgcttcgcg	2880
	aagcgtgtac	gcct-gggct	ttgaagtatg	ttttagctct	cagagcttct	acacatttctg	2940
40	atatcagaat	ttctgatatt	agccctttta	ataaagcagt	tactgtacct	aagaacagta	3000
	agacagatcg	ttgtattgct	atcgaaacctg	gttggaaatat	gtttttccaa	ctgggtatcg	3060
	gtggcattct	acgcgatcgg	ttgcgttgct	gggggtatcga	tctgaatgat	cagacgataa	3120
	atcagcgcgg	cgctacgaa	ggctccgtta	ctaataaact	agcaacgggt	gatctctcag	3180
	cggcaagcga	ttcttatct	cttgccctct	gtgagctctt	attgccccca	ggctgggttg	3240
45	aggttcttat	ggacttcaga	tcacctaagg	ggcgattgcc	tgacggtagt	gttggtacct	3300
	acgagaagat	ttctctatg	ggtaacgggt	acacattcga	gctcgagtcg	cttatttttg	3360
	cttctctcgc	tcgtccggtt	ttgtagatac	tggacttaga	ctcgtctgag	gtcactgttt	3420
	acggagacga	tattatttta	ccgtcctgtg	cagtcctcgc	cctccgggaa	gtttttaagt	3480
	atgttggttt	tacgaccaat	actaaaaaga	ctttttccga	ggggccgttc	agagagtcgt	3540
50	gcggaagca	ctactattct	ggcgtagatg	ttactccctt	ttacatacgt	caccgtatag	3600
	tgagtcctgc	cgatttaata	ctggttttga	ataacctata	tcggtgggac	acaattgacg	3660
	gcgtatggga	tcctagggcc	cattctgtgt	acctcaagta	tcgtaagttg	ctgcctaaac	3720
	agctgcaacg	taatactata	cctgatgggt	acggtgatgg	tgccctcgtc	ggatcggtcc	3780
	taatcaatcc	tttcgcaaaa	aaccgcgggt	ggatccggta	cgtaccgggtg	attacggacc	3840
55	atacaagggg	ccgagagcgc	gctgagttgg	ggctgatctt	ctacgacctc	ttctcgcggt	3900
	gtctctcgga	aagtaacgat	gggttgccctc	ttaggggtcc	atcgggttgc	gattctgcgg	3960
	atctatttgc	catcgatcag	cttatctgta	ggagtaatcc	tacgaagata	agcaggtcta	4020
	ccggcaaat	cgatatagc	tatatcgctg	cgagtagccg	tgttctggca	ccctacgggg	4080
	tcttccaggg	cacgaagggt	gcgtctctac	acgagggcga	acctggggagg	gcgccaatat	4140
60	ggcgctaat	tgtcaataaa	ttatcacaat	tactcttacg	agtgaagggg	ggatctgctt	4200
	tgccctctct	cctccggggg	gatccactag	ttctaaggta	tcgggcagcg	ttgggtcctg	4260

4/9

	gccacgggtg	cgcatgatcg	tgtcctgtgc	gttgaggacc	cggttaggct	ggcgggggtg	4320
	ccttactggg	tagcagaatg	aatcaccgat	acgcgagcga	acgtgaaagc	actgctgctg	4380
	caaaacgtct	gcgacstgag	caacaacatg	aatgggtctt	ggtttccgtg	tttcgtaaag	4440
	tctggaaacg	cggaagtcag	cgccctgcac	cattatgttc	cggatctgca	tcgcaggatg	4500
5	ctgctggcta	ccctgaggaa	cacctacatc	tgtattaacg	aagcgctggc	attgacctcg	4560
	agtgtttttt	ctctgggtccc	gccgcatcca	taccgccagt	tgtttaccct	cacaacgttc	4620
	cagtaaccgg	gcatgttcat	catcagtaac	cogtatcgtg	agcatcctct	ctcgtttcat	4680
	cggtatcatt	accccatga	acagaaattc	ccccttacac	ggaggcatca	agtgacccaa	4740
	caggaaaaaa	ccgccccttaa	catggcccgc	tttatcagaa	gccagacatt	aacgcttctg	4800
10	gagaaactca	acgagctgga	cgcgatgaa	caggcagaca	tctgtgaatc	gcttcacgac	4860
	cacgctgatg	agctttaccg	cagctgcctc	gcgcgtttcg	gtgatgacgg	tgaaaaacct	4920
	tgacacatgc	agctcccggg	gacggtcaca	gcttgtctgt	aagcggatgc	cgggagcaga	4980
	caagcccgtc	agggcgcgct	agcgggtggt	ggcggtgtgc	ggggcgagc	catgaccag	5040
	tcacgtagcg	atagcggagt	gtatactggc	tttaactatg	ggcatcagag	cagattgtac	5100
15	tgagagtgc	ccatacgcg	tgtgaaatac	cgcacagatg	cgtaaggaga	aaataccgca	5160
	tcaggcgctc	ttccgtttcc	tcgctcactg	actcgctcg	ctcggtcggt	cggctgcggc	5220
	gagcgggtatc	agctcactca	aaaggcggtaa	tacgggtatc	cacagaatca	ggggataacg	5280
	caggaaagaa	catgtgagca	aaaggccagc	aaaaggccag	gaaccgtaaa	aaggcccgct	5340
	tgctggcggt	tttccatagg	ctccgcccc	ctgacgagca	tcacaaaaat	cgacgtcaa	5400
20	gtcagagggtg	gcgaaacccg	acaggactat	aaagatacca	ggcgtttccc	cctggaagct	5460
	ccctcgtgcg	ctctctgtgt	ccgacctgc	cgcttaccgg	atacctgtcc	gcctttctcc	5520
	cttcgggaag	cgtggcgctt	tctcatagct	cacgctgtag	gtatctcagt	tcggtgtagg	5580
	tcgttcgctc	caagtggggc	tgtgtgcacg	aaacccccgt	tcagcccagc	cgctgcgcct	5640
	tatccggtaa	ctatcgtctt	gagtccaacc	cggtaagaca	cgacttatcg	ccactggcag	5700
25	cagccactga	taacaggatt	agcagagcga	ggtatgtagg	cgggtgctaca	gagttcttga	5760
	agtgtgtggc	taactacggc	tacactagaa	ggacagtatt	tggtatctgc	gctctgtctga	5820
	agccagttac	cttcggaaaa	agagttggta	gctcttgatc	cggcaaaaaa	accaccgctg	5880
	gtagcgggtg	ttttttgtgt	tgcaagcagc	agattacgcg	cagaaaaaaa	ggatctcaag	5940
	aagatccctt	gatcttttct	acgggggtctg	acgctcagtg	gaacgaaaaa	tcacgttaag	6000
30	ggatttttgt	catgagatta	tcaaaaaagga	ctttcaccta	gaccccttta	aattaaaaat	6060
	gaagttttta	atcaatctaa	agtatatatg	agtaaaactg	gtctgacagt	taccaatgct	6120
	taatcagtga	ggcacctatc	tcagcgatct	gtctatcttc	ttcatccata	gttgccctgac	6180
	tccccgctcg	gtagataaact	acgatacggg	agggcttacc	atctggcccc	agtgtgtcaa	6240
	tgataccgcg	agaccacgc	tcaccggctc	cagattttatc	agcaataaac	cagccagccg	6300
35	gaagggccga	gcgcagaagt	ggtcctgcga	ctttatccgc	ctccattcag	tctattaatt	6360
	gttgccggga	agctagagta	agtagttcgc	cagttaatag	tttgcgcaac	gttggttgcca	6420
	ttgctgcagg	catcgtgggtg	tcacgctcgt	cgtttggtat	ggcttcattc	agctccggtt	6480
	cccaacgatc	aaggcgaggt	acatgatccc	ccatgttggtg	caaaaaagcg	gttagctcct	6540
	tcggtcctcc	gatcgttggtc	agaagtaagt	tgccgcgagt	gttatcactc	atgggttatgg	6600
40	cagcactgca	taattctctt	actgtcatgc	catccgtaag	atgcttttct	gtgactgggtg	6660
	agtaactcaac	caagtcattc	tgagaatagt	gtatgcggcg	accgagttgc	tcttgcccg	6720
	cgtcaacacg	ggataatacc	gcgccacata	gcagaacttt	aaaagtgtc	atcattggaa	6780
	aacgttcttc	ggggcgaaaa	ctctcaagga	tcttacccgt	gttgagatcc	agttcgatgt	6840
	aacccactcg	tgcaaccaac	tgatcttcag	catcttttac	tttcaccagc	gtttctgggt	6900
45	gagcaaaaac	aggaaaggca	aatgccgcaa	aaaagggaat	aagggcgaca	cggaaatgtt	6960
	gaatactcat	actcttctct	tttcaatatt	attgaagcat	ttatcagggt	tattgtctca	7020
	tgagcggata	cataattgaa	tgtatttaga	aaaataaaca	aataggggtt	ccgcgcacat	7080
	ttccccgaaa	agtgcacct	gacgtctaa	aaaccattat	tatcatgaca	ttaacctata	7140
	aaaataggcg	tatcacgagg	ccctttcgtc	ttcaagaatt	ggcgaacgtg	gcgagaaaagg	7200
50	aagggaagaa	agcgaaagga	gcggcgctga	ggcgctggc	aagtgtagcg	gtcacgctgc	7260
	gcgtaaccac	cacacccgcc	gcgcttaatg	cgcgcgtaca	ggcgcgctcc	cattcgccat	7320
	tcaggctacg	caactgttgg	gaagggcgat	cgggtgcggc	ctcttcgcta	ttacgccagc	7380
	tgggcaaggg	gggaagtgtg	gcaaggcgat	taagttgggt	aacgccaggg	ttttccagct	7440
55	cacgacgttg	taaaacgacg	gccagtgaat	tgtaatacga	ctcactata		7489

SEQ ID NO: 6

<211> 1716

<212> DNA

<213> Hepatitis C virus

60

<220>

5/9

<223> Description of Sequence:Virus HCV NS5B

```

<400> 6
5  tctatgtcgt actcttggac cggcgccctg ataacaccgt gtagtgctga ggaggagaaa 60
   ctgcccatac gcccaattcag caactccttg ctgagacatc ataacctagt ctattcaacg 120
   tcgtctagaa gcgcttctca gcgtcagagg aaggttacct tcgacagact gcaggtgctc 180
   gacgaccatt acaagactgt attaaaggag gtaaaggagc gagcgtctag ggtaaaggct 240
   cgcattgctca ccattcaggga agcgtgcgcg ctcgccctc ctcaactctgc ccggtcgaaa 300
   ttcgggtata gtgcgaaggga cgttcgctcc ttgtctagca gggccattaa ccagatccgc 360
10  tccgtctggg aggaattgct agaagacacc acaactccaa ttccaaccac catcatggcg 420
   aagaacgagg tggttttgtt ggaccccgct aaagggggcc gcaagcccg cgccttatc 480
   gtgtaccctg acctgggggt tcgtgtctgc gagaaacgcg ccctatatga cgtgatacag 540
   aagttggcaa ttgagtcgat tggttctgct tacggattcc aatactcgcc tcaacagcgg 600
   gtcgaacgct tgctcaagat gtggacctca aagaaaacc ccttgggggt ctcgatgac 660
15  acccgctgct ttgactcaac tgtcactgaa caggacatca gggtggaaga ggagatatac 720
   caatgctgca accttgaacc ggaggccagg aaagtgatct cctccctcac ggagcggctt 780
   tactgcgggg gccctatgtt caacagcaag ggggctcagt gtggtgaccg tcgttgccgt 840
   gccagtggag ttttgcttac cagctttggc aatacaatca cttgtttacat caaagccaca 900
   gcggctgcga acggcgcagg cctccgggac ccggactttc ttgtctgcgg agatgatctg 960
20  gtcgtggtgg ccgagtgatg cggcgtcgat gaggatgggg cagccctgag agccttcacg 1020
   gaggttatga ccagctattc tgcctcaccg ggagatgctc cacagccac ctacgacctt 1080
   gagctcatca catcttctc ctccaacgct tccgtggcac gggacgacaa ggggaggagg 1140
   tactattacc tcacctgtga tgccaccact cccctagccc gtgcggtctg ggaaacagct 1200
   cgtcacactc cagttactc ctggttaggt aacatcatca tgtaacgcgc taccatctgg 1260
25  gtgcgcatgg taatgatgac acacttttcc tccatactcc aatcccagga gatacttgat 1320
   cgaccccttg acttcgaaat gtacggggcc acttactcgg tcacgcgcgt ggattttacca 1380
   gcaatcattg aaagattcca tggcttaagc gcgttcacgc tccacagtta ctctccagta 1440
   gagctcaata gggctcggg gacactcagg aagctggggg gccccccctt acgagcttgg 1500
   agacatcggg cagcagcagg gcgcgctaag cttatcgccc agggagggaa ggccaaaata 1560
30  tgcgcccttt atctctttaa ttgggcggtg cgcaccaaga ccaaactcac tccgctgcca 1620
   cgcgctggcc agttggtatt atccatctgg ttacggttg gcgtcggcgg gaacgacatt 1680
   tatcacagcg tgctcgtgc ccgaaccgcg tattag 1716

```

SEQ ID NO: 7

```

35  <211> 65
     <212> DNA
     <213> Artificial Sequence

```

```

40  <220>
     <223> Description of Artificial Sequence:Artificial
         primer

```

```

45  <400> 7
     gcgcgaatac gactcctat agagggacaa accgccatgg ccgaggtgag gcttcttgag 60
     tctgg 65

```

SEQ ID NO: 8

```

50  <211> 58
     <212> DNA
     <213> Artificial Sequence

```

```

55  <220>
     <223> Description of Artificial Sequence:Artificial
         primer

```

```

     <400> 8
     catcatcatc atcttataa tctgcggccg cacactctcc cctgttgaag ctcttgac 58

```

6/9

SEQ ID NO: 9
 <211> 57
 <212> DNA
 5 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:Artificial
 primer
 10
 <400> 9
 cccctgttga agctcagac aatgggtgaa gttgatgtct tgtgagtggc ctcacag 57

 SEQ ID NO: 10
 15 <211> 46
 <212> DNA
 <213> Artificial Sequence

 <220>
 20 <223> Description of Artificial Sequence:Artificial
 primer

 <400> 10
 25 cttgtgagtg gcctcagagg tatagctgtt atgtcgttca tactcg 46

 SEQ ID NO: 11
 <211> 55
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Description of Artificial Sequence:Artificial
 primer

 35 <400> 11
 accatgatta cgccaagctc taatacgact cactataggg aaagctcgct tgttc 55

 SEQ ID NO: 12
 <211> 60
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:Artificial
 45 primer

 <400> 12
 agggaaagct cgcttcttct tttgcagaa gtcagaata aacgctcaac tttggccacc 60

 50 SEQ ID NO: 13
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Description of Artificial Sequence:Artificial
 primer

 <400> 13
 60 tttataatct gcggcgccg cctcgtgtag agacgcaac 39

SEQ ID NO: 14
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence:Artificial
 primer
 10 <400> 14
 ttactcgcgg cccagccggc catggccatg tctaagacag catcttcg 48
 SEQ ID NO: 15
 <211> 60
 15 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:Artificial
 20 primer
 <400> 15
 gcagctaata cgactcacta taggaacaga ccaccatgga cgtggcccag cctgctgtgg 60
 25 SEQ ID NO: 16
 <211> 50
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence:Artificial
 primer
 <400> 16
 35 aaacgctcaa ctttgccac catggatgtg aagcttcagg agtctgggcc 50
 SEQ ID NO: 17
 <211> 51
 <212> DNA
 40 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:Artificial
 primer
 45 <400> 17
 gcccttgggc cgggagatgg tctgcttcag tggcgagggc aggtctgtgt g 51
 SEQ ID NO: 18
 50 <211> 49
 <212> DNA
 <213> Artificial Sequence
 <220>
 55 <223> Description of Artificial Sequence:Artificial
 primer
 <400> 18
 cgagggcagg tctgtgtggg tcacgggtgca cgtgaacctc tccccggag 49

8/9

SEQ ID NO: 19
<211> 51
<212> DNA
5 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Artificial
primer
10

<400> 19
cgtgaacctc tccccggagt tccagtcac ctcgcagatg ctggcctcac c 51

SEQ ID NO: 20
15 <211> 65
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Description of Artificial Sequence:Artificial
primer

<400> 20
gcggaatac gactcattat agaggacaa accgccatgg ccgatgtgaa gcttcaggag 60
25 tcagg 65

SEQ ID NO: 21
30 <211> 60
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Description of Artificial Sequence:Artificial
primer

<400> 21
gcagctaata cgactcacta taggaacaga ccaccatgga cgtggcccag cctgctgtgg 60

40 SEQ ID NO: 22
<211> 54
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence:Artificial
primer

<400> 22
50 taatacgact cactataggg aaagggtttc tccgatccgg gaacatagga tacc 54

SEQ ID NO: 23
<211> 61
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Artificial
primer

9/9

5 <400> 23
tgaggatatcc tatgttcccg gatcggagaa acccacactc tcccctgttg aagctcttga 60
c 61

10 SEQ ID NO: 24
<211> 56
<212> DNA
<213> Artificial Sequence

15 <400> 24
ccggaacat aggatacctc aaccacatg gccgaggtga ggcttcttga gtctgg 56

20 SEQ ID NO: 25
<211> 23
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:Artificial
primer

30 <400> 25
gaggtgaggc ttcttgagtc tgg 23

35 SEQ ID NO: 26
<211> 22
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence:Artificial
primer

<400> 26
gctgttatgt cgttcatact cg 22

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/AU 99/00341
A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: C12N 15/01 C12N 15/09 C12P 21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 WPAT, CHEM ABS SEE BELOW

 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 MEDLINE SEE BELOW

 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 WPAT: ((RNA dependent RNA polymerase) or (RNA directed RNA polymerase) or (RNA synthetase) or (RNA replicase) or (beta replicase)) and (mutant# or mutagen: or mutat: or amplif: or detect:) cont. on supplemental sheet.
C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 602 001 (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK) 11 February 1997 See abstract and summary of the invention.	34-40, 44, 45
Y	Proc. Natl. Acad. Sci. USA 93, pages 11558-62 (1996) Brown, D. and Gold, L. "RNA replication by Q β replicase: A working model." See the discussion	34-40, 44, 45

☒ Further documents are listed in the
 continuation of Box C

☒ See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

 Date of the actual completion of the international search
 28 May 1999

 Date of mailing of the international search report
 22 JUN 1999

 Name and mailing address of the ISA/AU
 AUSTRALIAN PATENT OFFICE
 PO BOX 200
 WODEN ACT 2606
 AUSTRALIA
 Facsimile No.: (02) 6285 3929

Authorized officer

TERRY MOORE
 Telephone No.: (02) 6283 2569

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00341

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. Biol. Chem. 269(2), pages 1501-5 (1994) Ryabova, L. et al. "Coupled replication-translation of amplifiable messenger RNA." See the entire document.	34-40, 44, 45
X	WO A 94/06928 (THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK) 31 March 1994 See pages 2-5.	34-40, 44, 45
X	Proc. Natl. Acad. Sci. USA 90, pages 9325-9 (1993) Morozov, I.Y. et al. "Synergism in replication and translation of messenger RNA in a cell-free system." See entire document and in particular figure 1B.	34-40, 44, 45
A	J. Mol. Biol. 249, pages 756-62 (1995) Rohde, N. et al. "The mutant distribution of an RNA species replicated by Q β replicase." See entire document.	1-45
A	Biophys. Chem. 66, pages 179-92 (1997) Biebricher, C.K. and Gardiner, W.C. "Molecular evolution of RNA <i>in vitro</i> ." See entire document.	1-45

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00341

Box supplemental

Continuation of Box B

CHEM ABS and MEDLINE: ((Q beta replicase) or (RNA dependent RNA polymerase) or (RNA replicase)) and (((cell free)(3n)(system) or (replication translation) or (translation transcription)))

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/00341

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
US	5 602 001	CA	1339856	AU	73068/87
		EP	346594		
WO	9406928	US	5 556 769	WO	8706270
					END OF ANNEX